

MASTER TIME TABLE for Phase 2  
(Batch Feb 2022 to Nov 2022)

**Number of Weeks**

Sr No	Dates ( 1 <sup>st</sup> Term)	
1	7.2.22 to 12.2.22	
2	14.2.22 to 19.2.22	
3	21.2.22 to 26.2.22	
4	28.2.22 to 5.3.22	
5	7.3.22 to 12.3.22	
6	14.3.22 to 19.3.22	
7	21.3.22 to 26.3.22	
8	28.3.22 to 2.4.22	
9	4.4.22 to 9.4.22	
10	11.4.22 to 16.4.22	
11	18.4.22 to 23.4.22	
12	25.4.22 to 30.4.22	
13	2.5.22 to 7.5.22	
14	9.5.22 to 14.5.22	
15	16.5.22 to 21.5.22	1 <sup>st</sup> Term ending Exam
16	23.5.22 to 30.5.22	1 <sup>st</sup> Term ending Exam

Sr No	Dates (2 <sup>nd</sup> Term)	
1	31.5.22 to 4.6.22	
2	6.6.22 to 11.6.22	
3	13.6.22 to 18.6.22	
4	20.6.22 to 25.6.22	
5	27.6.22 to 2.7.22	
6	4.7.22 to 9.7.22	
7	11.7.22 to 16.7.22	
8	18.7.22 to 23.7.22	
9	25.7.22 to 30.7.22	

10	1.8.22 to 6.8.22	
11	8.8.22 to 13.8.22	2 <sup>nd</sup> Term ending exam
12	15.8.22 to 22.8.22	2 <sup>nd</sup> Term ending exam

Sr No	Dates ( 3 <sup>rd</sup> Term)	
1	23.8.22 to 27.8.22	
2	19.8.22 to 3.9.22	
3	5.9.22 to 10.9.22	
4	12.9.22 to 17.9.22	
5	19.9.22 to 24.9.22	
6	26.9.22 to 1.10.22	
7	3.10.22 to 8.10.22	
8	10.10.22 to 15.10.22	
9	17.10.22 to 22.10.22	
10	24.10.22 to 29.10.22	Diwali Vacation
11	31.10.22 to 5.11.22	
12	7.11.22 to 12.11.22	Prelim Exam
13	14.11.22 to 19.11.22	Prelim Exam

**November 2022: Prelim**

**Dec 2022: Final exam**

Terms	Teaching weeks
1 <sup>st</sup> Term	14weeks + 2 weeks exam
2 <sup>nd</sup> Term	10 weeks + 2 weeks exam
3 <sup>rd</sup> Term	10 weeks+ 2 weeks exam
<b>TOTAL</b>	<b>40 weeks</b>

**1<sup>st</sup> BLOCK: ( 1<sup>st</sup> February to 28<sup>th</sup> May 2022): 14 Teaching weeks + 2 weeks Exam**

	Mon	Tues	Wed	Thurs	Fri
8:30-9:30am	CM	Micro	Med	FMT	Surg
9:30 – 12:30pm	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting
12:30-1:30pm	Lunch				
1:30 – 2:30pm	Pharm	Pharm	Patho	Micro	Patho
2:30-4:30pm	Patho (Batch A)	Micro(Batch A)	Patho (batch B)	Micro(Batch B)	Pharm
	Pharm (Batch B)	CM (Batch B)	Pharm (Batch A)	C M (Batch A)	
	1 <sup>st</sup> Sat	2 <sup>nd</sup> Sat	3 <sup>rd</sup> Sat	4 <sup>th</sup> Sat	5th Sat
8:30-9:30am	OBGY	OBGY	OBGY	OBGY	OBGY
9:30 – 10:30am	AETCOM	Micro	AETCOM	Micro	Micro
10:30-11:30am	AETCOM	FMT	AETCOM	FMT	CM
11:30-1:30pm	Patho	Patho	Patho	Patho	Patho
1:30 Onwards	Sports	Sports	Sports	Sports	Sports

**2<sup>nd</sup> BLOCK (31st May to 20<sup>th</sup> August 2022): 10 teaching weeks+2 weeks Exam**

	<b>Mon</b>	<b>Tues</b>	<b>Wed</b>	<b>Thurs</b>	<b>Fri</b>
8:30-9:30am	Micro	Surg	Med	Micro	OBGY
9:30 – 12:30pm	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting
12:30-1:30pm	Lunch				
1:30 – 2:30pm	Pharm	CM	Patho	Pharm	Micro
2:30-4:30pm	Patho	Pharm	Micro(Batch A)	Patho(Batch B)	Patho (Batch A)
			Pharm (Batch B)	FMT (Batch A)	FMT (Batch B)
	<b>1<sup>st</sup> Sat</b>	<b>2<sup>nd</sup> Sat</b>	<b>3<sup>rd</sup> Sat</b>	<b>4<sup>th</sup> Sat</b>	<b>5<sup>th</sup> Sat</b>
8:30-9:30am	AETCOM	FMT	AETCOM	FMT	FMT
9:30 – 10:30am	AETCOM	CM	AETCOM	CM	CM
10:30-11:30am	Patho	Patho	Patho	Patho	Patho
11:30-1:30pm	Micro(Batch B)	Micro(Batch B)	Micro(Batch B)	Micro(Batch B)	Micro(Batch B)
	Pharm (Batch A)	Pharm (Batch A)	Pharm (Batch A)	Pharm (Batch A)	Pharm (Batch A)
1:30 Onwards	Sports/ECA	Remedial Pharmac	Remedial Patho	Remedial Micro	Sports/ ECA

**3<sup>rd</sup> BLOCK (23<sup>rd</sup> August to 30<sup>th</sup> Nov, 2022) : 11 Teaching weeks + 2 weeks exam**

	Mon	Tues	Wed	Thurs	Fri
8:30-9:30am	Patho	Pharm	Micro	Micro	Patho
9:30 – 12:30pm	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting	Clinical Posting
12:30-1:30pm	Lunch				
1:30 – 2:30pm	Micro	Patho	Patho	Pharm	Micro
2:30-4:30pm	Pharm	Patho	Pharmac	Pharmac	Patho (Batch B)
					Micro (Batch A)
	1 <sup>st</sup> Sat	2 <sup>nd</sup> Sat	3 <sup>rd</sup> Sat	4 <sup>th</sup> Sat	5 <sup>th</sup> Sat
8:30-9:30am	Aetcom	Pharm	Aetcom	Pharm	Aetcom
9:30 – 10:30am	Aetcom	Pharm	Aetcom	Pharm	Aetcom
10:30-11:30am	Micro	Micro	Micro	Micro	Pharm
11:30-1:30pm	Patho (Batch A)	Patho (Batch A)	Patho (Batch A)	Patho (Batch A)	Patho (Batch A)
	Micro (Batch B)	Micro (Batch B)	Micro (Batch B)	Micro (Batch B)	Micro (Batch B)
1:30 Onwards	Sports/ECA	Remedial Pharmac	Remedial Patho	Remedial Micro	Sports/ ECA

Calculation of Teaching Hours for Phase 2

Subject	NMC/ MCI Requirement	1 <sup>st</sup> Term	2 <sup>nd</sup> Term	3 <sup>rd</sup> Term	TOTAL
		(14 teaching Weeks)	(10 Teaching weeks)	(10 Teaching weeks)	
Patho	230	84	60	80	224
Pharm	230	84	60	70	214
Micro	190	49	50	70	169
OBGY	25	14	10	-	24
Med	25	14	10	-	24
Surg	25	14	10	-	24
FMT	50	21	26	-	47
Commu Med	60	43	16	-	59
Sports	28	14	10	-	24
Aetcom	37	14	10	10	34

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
7.3.22	Mon	FMT (L) <b>FM1.9</b> Describe the importance of documentation in medical practice in regard to medicolegal examinations, Medical Certificates and medicolegal reports especially - maintenance of patient case records, discharge summary, prescribed registers to be maintained in Health Centres. - maintenance of medico-legal register like accident register. - documents of issuance of wound certificate - documents of issuance of drunkenness certificate. - documents of issuance of sickness and fitness certificate. - documents for issuance of death certificate. -documents of Medical Certification of Cause of Death - Form Number4 and 4A - documents for estimation of age by physical, dental and radiological examination and issuance of certificate <b>FM1.10</b> - Select appropriate cause of death in a particular scenario by referring ICD 10 code	Clinical Posting			Pharm- PH 1.13 (L) - Adrenergic agonists (Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs) ( Alpha blockers)	Micro (DOAP )-MI 1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:Gram Staining certification(DOAP) Batch A CM8.4,8.5 (Batch B) STD, Yaws (SGT)	Micro (DOAP )-MI 1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:Gram Staining certification (DOAP) Batch A CM 8.4,8.5 (Batch B) Syndromic Approach (SGT)
8.3.22	Tues	IM 3.1, 3.2: (L) Define, discuss, describe and distinguish community acquired pneumonia, nosocomial pneumonia and aspiration pneumoniDiscuss and describe the aetiologies of various kinds of pneumonia and their microbiologya	Clinical Posting			PA6.6ischemia ,Infarction: Define types with clinical significance.(L)	PA 4.4Acute inflammation ,Chronic inflammation & repair.DOAP Batch A	Pharm (Batch B)-- PH2.1 Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) - Parentral route (DOAP)
9.3.22	Wed	MI1.6:Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy: Bacterial Genetics 2 (L)	Clinical Posting			MI 1.6: Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy: Minimisation of Drug resistance (SG)	Micro (DOAP )-MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Gram Staining (Certification)(DOAP) Batch BCM8.4,8.5 (Batch A) STD, Yaws (SGT)	Micro (DOAP )-MI 1.1: Gram Staining (Certification) (DOAP) Batch B CM 8.4,8.5 (Batch A) Syndromic Approach (SGT)
10.3.22	Thurs	SU 6.1 (L) Define and describe the aetiology and pathogenesis of surgical infections SU 6.2 Enumerate Prophylactic and therapeutic antibiotics Plan appropriate management	Clinical Posting			PA7.1Nomenclature, classification & differentiation between benign & malignant neoplasms.Precancerous lesions. (L)	PA7.2Molecular basis of cancer & Biology of tumor growth(L)	Pharmac (L)- Pharm - PH 1.13 Alpha adrenergic antagonist (Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs) - Alpha blocker (L)

11.3.22	Fri	OG 8.1: (L) Enumerate, describe and discuss the objectives of antenatal care,assessment of period of gestation; screening for high-risk factors.	9:30 – 10:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)	Pharmac (L)- Pharm - PH 1.13 Beta adrenergic antagonist (Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs) (L)	MI 12.6 (SDL): Widal	Sports	
			10:30- 11:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)				
			11:30- 12:30pm	PA7.3Carcinogenesis(L)				
12.3.22	2nd Sat	SU 4.1 (L) Elicit document and present history in a case of burns and perform physical examination. Describe Pathophysiology of Burns SU 4.2 Describe Clinical features, Diagnose type and extent of burns and plan appropriate treatment. SU 4.3 Discuss the Medicolegal aspects in burn injuries. SU 4.4 Communicate and counsel patients and families on the outcome and rehabilitation demonstrating empathy and care	9:30 – 10:30pm	PA 9.1: Principles and mechanisms involved in immunity. PA 9.2 Hypersensitivity reactions: Types & differentiate between different types of hypersensitivity reactions. (L)	Pharm - SGT PH1.14 (Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs )Anticholinesterases and Rx of Organophosphorus poisoning			
			10:30- 11:30pm	PA 8.1: Cytology and its application including FNAC & PA 8.2 Describe the basis of exfoliative cytology including the technique & stains used. (Tutorials).Batch A				



11:30-12:30pm	Pharm - SGT PH1.14 (Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs )Anticholinesterases and Rx of Organophosphorus poisoning
---------------	---

1st March to 6th March								
Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm	
7.2.22	Mon	Orientation all subjects 9:30am to 11am	Clinical Posting	Lunch	PH1.1 &1.9 (L) Intro to Pharmacology (Define and Describe the principle of Pharm)	PA13.2Anticoagulants , Blood collection & Hb Estimation(DOAP)	Pharm (Batch B) Practical PH 2.1: Route of administration oral (Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) Intoduction to Pharmacology (DOAP)	
8.2.22	Tues	FMT (L) FM1.1 Demonstrate knowledge of basics of Forensic Medicine like definitions of Forensic medicine, Clinical Forensic Medicine, Forensic Pathology, State Medicine, Legal Medicine and MedicalJurisprudence FM1.2 Describe history of Forensic Medicine	Clinical Posting		PH 1.3, 1.11: (L) Routes of drug administration enumerate and Identify formulations	Micro (DOAP )MI1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection Microscopy Batch A CM 8.4, 8.5 BatchB Influenza SGT	Micro (DOAP )-MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detectionMicroscopy (DOAP) Batch A CM 8.4, 8.5 SARs (SGT) Batch B	
9.2.22	Wed	IM 4.1, 4.2, 4.3: (L) Describe and discuss the febrile response and the influence of host immune status, risk factors and comorbidities on the febrile responseDescribe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia, HIV and travelDescribe and discuss the influence of special populations on the febrile response including: the elderly, immune suppression, malignancy and neutropenia, HIV and travelDiscuss and describe the common causes, pathophysiology and manifestations of fever in various regions in India including bacterial, parasitic and viral causes (e.g.Dengue, Chikungunya, Typhus)	Clinical Posting		PA1.1, 1.2, &1.3 Introduction to Pathology (L)	PA13.2Anticoagulants , Blood collection & Hb Estimation(DOAP) Batch B	Pharm (Batch A) Practical PH 2.1: Route of administration oral (Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) Intoduction to Pharmacology (DOAP)	
10.2.22	Thurs	MI 1.1 Describe the different causative agents of Infectious diseases+A208the methods used in their detection: History of Microbiology (L)	Clinical Posting	Lunch	MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection Bacterial Morphology (L)	Micro (DOAP )-MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detectionMicroscopy (DOAP) Batch B CM 8.4, 8.5 BatchA Influenza SGT	Micro (DOAP )-MI1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection Microscopy (DOAP) Batch B Batch A CM 8.4, 8.5 SARs (SGT)	
11.2.22	Fri	SU 2.1 (L) Describe Pathology of shock, types of shock & principles of resuscitation including fluid replacement and monitoring. SU 2.2 Describe the clinical features of shock and its appropriate treatment SU2.3 Communicate and counsel patients and famillies about the treatment and prognosis of shock demonstrating empathy and care	Clinical Posting		PA 2.1: Demonstrate knowledge of the causes, mechanisms, types and effects of cell injury and their clinical significance (L)	PA 2.2: Describe the etiology of cell injury. Distinguish between reversible-irreversible injury: mechanisms; morphology of cell injury. (L)	PH1.4Describe absorption of drugs (L)	
12.2.22	2nd Sat	OG 5.1 (L) Describe, discuss and identify pre-existing medical disorders and discuss their management; discuss evidence-based intrapartum care	9:30 – 10:30pm	AETCO2.2: The foundations of bioethics (Pharmac)2.3: Health care as a right (FMT)	PH1.4Describe distribution of drugs (SGT)	SPORTS	SPORTS	
			10:30-11:30pm	AETCO2.2: The foundations of bioethics (Pharmac)2.3: Health care as a right (FMT)				
			11:30-12:30pm	PA 2.3 : Intracellular accumulation of fats, proteins, carbohydrates, pigments. (L)				



Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
14.2.22	Mon	Measles (L) CM 8.4, 8.5	Clinical Posting		Lunch	PH 1.4 (L) Drug Metabolism . PH 1.51 Describe occupational and environmental pesticides, food adulterants, pollutants and insect repellents	PA2.6Retogressive changes & disorders of cell growthsDOAP Batch A	(Batch B) PH1.10 and 5.7 -Practical Introduction to Pharmacy and prescription writting (Describe vaarious parts of correct , complete and legible generic prescription and correct appropriately Demonstrate an understanding of the legal and ethical aspects of prescribing drugs (DOAP)
15.2.22	Tues	FMT (L) FM 1.3 - Describe legal procedures including Criminal Procedure Code, Indian Penal Code, Indian Evidence Act, Civil and Criminal Cases, Inquest (Police Inquest and Magistrate’s Inquest), Cognizable and Non-cognizable offences FM1.4 - Describe Courts in India and their powers: Supreme Court, High Court, Sessions court, Magistrate’s Court, Labour Court, Family Court, Executive Magistrate Court and Juvenile Justice Board	Clinical Posting			PH1.8 Identify and describe the management of drug interactions PH1.2Describe the basis of Evidence based medicine and Therapeutic drug monitoring (L)	Micro (DOAP )-MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:Morphology of Bacteria (DOAP) Batch A CM 8.4, 8.5 BatchB Mumps SGT	Micro (DOAP )-MI1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Morphology of Bacteria (DOAP) Batch A CM 8.4, 8.5 Rubella (SGT) (Batch B)
16.2.22	Wed	IM 4.6:(L) Discuss and describe the pathophysiology and manifestations of malaria	Clinical Posting			PA 2.7 Cellular ageing and mechanism(L)	PA2.6 Retogressive changes & disorders of cell growths (DOAP) Batch B	(Batch A) PH1.10 and 5.7 -Practical Introduction to Pharmacy and prescription writting (Describe vaarious parts of correct , complete and legible generic prescription and correct appropriately Demonstrate an understanding of the legal and ethical aspects of prescribing drugs (DOAP)
17.2.22	Thurs	M1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detectionPhysiology and Metabolism of Bacteria (L)	Clinical Posting			MI 1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Culture Medias (SG)	Micro (DOAP )MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detectionMorphology of Bacteria (DOAP) Batch B CM 8.4, 8.5 BatchA Mumps SGT	Micro (DOAP )MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Morphology of Bacteria (DOAP) Batch B CM 8.4, 8.5 Rubella (SGT) Batch A
18.2.22	Fri	SU 1.1 (L) Describe Basic concepts of homeostasis,enumerate the metaboloic changes in injury and their mediators SU1.2 Describe the factors that effect the metabolic response to injury SU 1.3 Describe basic concepts of perioperative care	Clinical Posting			PA 2.4:Describe and discuss Cell death- types, mechanisms, necrosis, apoptosis (basic as contrasted with necrosis), autolysis (L)	PA 2.5: Calcification and Gangrene (L)	PH 1.4 (SGT) Excretion
19.2.22	3rd Sat	PUBLIC HOLIDAY- SHIV JAYANTI						

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
21.2.22	Mon	CM 8.4, 8.5: Acte diarrheol disease ( L )	Clinical Posting	Lunch	PH 1.5 Pharmacodynamics 1 ( L ) (Describe general principles of mechanism of drug action)	PA2.8Necrosis & gangrene(DOAP) Batch A	PH 2.1 Pharm Practical (Batch B) Route of Administration- Oral(Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) (DOAP)
22.2.22	Tues	FMT (L) FM1.5 - Describe Court procedures including issue of Summons, conduct money, types of witnesses, recording of evidence oath, affirmation, examination in chief, cross examination, re-examination and court questions, recording of evidence & conduct of doctor in witness box FM1.6 - Describe Offenses in Court including Perjury; Court strictures vis-avis Medical Officer	Clinical Posting		PH 1.5 Pharmacodynamics 2 ( L ) (Describe general principles of mechanism of drug action)	Micro (DOAP )MI1.4:Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Sterilisation and Disinfection (DOAP) Batch A CM 8.5, 8.6 (Batch B) Food Poisoaning	Micro (DOAP )MI1.4: Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Sterilisation and Disinfection (DOAP) Batch A CM 8.6, 8.5 Salmonellosis (SGT)
23.2.22	Wed	Im 4.22:(L) Describe and discuss the pharmacology, indications, adverse reactions, interactions of antimalarial drugs and basis of resistance	Clinical Posting		PA 4.2: Chemical mediators of inflammation: definition, classification, description of each type, role in acute & chronic inflammation. (L)	PA2.8Necrosis & gangrene(DOAP) Batch B	PH 2.1 Pharm Practical (Batch B) Route of Administration- Oral(Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) (DOAP)
24.2.22	Thurs	MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Culture Methods (L)	Clinical Posting		MI 1.4: Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Sterilisation (L)	Micro (DOAP )MI1.4: Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Sterilisation and Disinfection (DOAP) Batch B CM 8.5, 8.6 (Batch A) Food Poisoaning	Micro (DOAP )MI1.4:Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Sterilisation and Disinfection (DOAP) Batch B Batch A CM 8.6, 8.5 Salmonellosis (SGT)
25.2.22	Fri	SU 5.1 (L) Describe normal wound healing and factors affecting healing SU 5.2 Elicit, document and present a history in a patient presenting with wounds. SU 5.3 Differentiate the various types of wounds. Plan and observe management of wounds. SU 4.5 Discuss Medico legal aspects of wounds	Clinical Posting		PA 4.3: Chronic inflammation: definition & causes. Granulomatous inflammation: etiology, pattern & systemic effects of granulomas.(L)	PA 5.1: Regeneration & repair: Healing by primary & secondary intention with local & systemic factors affecting wound healing. Repair in specialized tissue.(L)	PH 1.5 (SGT) Factors modifying drug action ( Describe general principles of mechanism of drug action )

26.2.22	4TH Sat	OG 6.1 (L)Describe, discuss and demonstrate the clinical features of pregnancy, derive and discuss its differential diagnosis, elaborate the principles underlying and interpret pregnancy tests.	9:30 – 10:30pm	AETCOM2.3: Health care as a right (FMT) 2.2: The foundations of bioethics (Pharmac)	PH1.6 Describe principles of Pharmacovigilance & ADR reporting systems PH1.7Define, identify and describe the management of adverse drug reactions (ADR) (L)	SPORTS	SPORTS	
			10:30- 11:30pm	AETCOM2.3: Health care as a right (FMT) 2.2: The foundations of bioethics (Pharmac)				
			11:30- 12:30pm	PA6.2Hyperemia, congestion, hemorrhage(L).				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm	
28.2.22	Mon	CM8.4 8.5, Chicken Pox, Small pox (L)	Clinical Posting	Lunch	Ph 1.63 (L) Describe drug regulations, acts and legal aspects Drug Regulations and Schedules	PA 3.2Amyloidosis: morphology, lab diagnosis with special stain.DOAP Batch As	Pharm (Batch B) Practical-PH 2.1 Route of Administration-Topical (Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)	
1.3.22	Tues	FMT (L) FM1.7 - Describe Dying Declaration & Dying Deposition FM1.8 - Describe the latest decisions/notifications/resolutions/circulars/standing orders related to medico-legal practice issued by Courts/ Government authorities etc.	Clinical Posting		PH1.64 Describe overview of drug development, Phases of clinical trials and Good Clinical Practice (L) PANDEMIC MODULE	Micro (DOAP )-MI1.1.:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Diagnostic Microbiology 1 (DOAP) Batch A CM 8.4, 8.5, Batch B Meningococcal Meningitis (SGT)	Micro (DOAP )MI1.1.:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Diagnostic Microbiology 1 (DOAP) Batch A CM CM 8.4, 8.5, Batch B Acute Respiratory Infections	
2.3.22	Wed	IM 4.7: (L) Discuss and describe the pathophysiology and manifestations of the sepsis syndrome	Clinical Posting		PA 6.1: Edema: Define, classify, pathogenesis & correlate morphology with clinical significance.(L)	PA 3.2Amyloidosis: morphology, lab diagnosis with special stain.DOAP Batch B	Pharm (Batch A) Practical -PH 2.1 Route of Administration-Topical (Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liqu	
3.3.22	Thurs	MI 1.4:Classify and describe the different methods of sterilization and disinfection. Discuss the application of the different methods in the laboratory, in clinical and surgical practice: Disinfection (L)	Clinical Posting		MI 1.5: Choose the most appropriate method of sterilization and disinfection to be used in specific situations in the laboratory, in clinical and surgical practice: Disinfection (Lab, OT, OPD) Integrated	Micro (DOAP )-MI1.1.:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Diagnostic Microbiology 1 (DOAP) Batch B CM 8.4, 8.5, Batch A Meningococcal Meningitis (SGT)	Micro (DOAP )-MI1.1.: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:Diagnostic Microbiology 1 (DOAP) CM CM 8.4, 8.5, Batch A Acute Respiratory Infections	
4.3.22	Fri	SU 3.1 (L) Describe the indications and appropriate use of blood and blood products and complications of blood transfusion SU 3.2 Observe blood transfusions. SU 3.3 Counsel patients and family /friends for blood transfusion and blood donation	Clinical Posting		PA6.4Thrombosis: Definition, etiopathogenesis, morphology, fate & effects of thrombosis.(L)	PA6.5Embolism : Define types with clinical significance.(L)	PH1.60 Describe and discuss Pharmacogenomics and Pharmacoeconomics (SGT)	
5.3.22	1st Sat	OG 7.1: (L)Describe and discuss the changes in the genital tract,cardiovascular system, respiratory, haematology, renal and gastrointestinal system in pregnancy	9:30 – 10:30pm	MI1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: Bacterial Genetics 1 (L)	PH 1.13 Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs-II (SGT)	Sports	Sports	
			10:30-11:30pm	PH 1.13 Describe mechanism of action, types, doses, side effects, indications and contraindications of adrenergic and anti-adrenergic drugs -I (L)	-			
			11:30-12:30pm	PA6.3Shock: Define, classify, pathogenesis, mediators & stages of shock.(L)	-			

Pharm- ( L) PH 1.8 Drug interactions and TDM (Identify and describe the management of drug interactions )Pharmac (L)

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
14.3.22	Mon	CM 8.4, 8.5 Epidemiology of TB & Elimination (L)	Clinical Posting		Lunch	Pharm- PH 1.4 Cholinergic (Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs) (L)	PA 4.4Acute inflammation ,Chronic inflammation & repair.DOAP ( Batch B)	Pharm (Batch A)– PH2.1 Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid) - Parenteral route (DOAP)
15.3.22	Tues	FMT (L)  FM1.11 - Write a correct cause of death certificate as per ICD 10 document  FM2.1 - Define, describe and discuss death and its types including somatic/ clinical/ cellular, molecular and brain-death, Cortical Death and Brainstem Death	Clinical Posting			Pharm- PH 1.4 (L) Anticholinergic (Describe mechanism of action, types, doses, side effects, indications and contraindications of cholinergic and anticholinergic drugs) (L)	Micro (DOAP )-MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: ZN Staining (DOAP) Batch A CM 8.4, 8.5 (Batch B) Lymphatic Filariasis (SGT)	Micro (DOAP )-MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: ZN Staining (DOAP) Batch A CM 8.4, 8.5 (Batch B) Yellow fever, JE (SGT)
16.3.22	Wed	IM 3.3, 3.15, 3.16 (Integrated-AITO): Discuss and describe the pathogenesis, presentation, natural history and complications of pneumoniDescribe and enumerate the indications for hospitalisation in patients with pneumoniaaDescribe and enumerate the indications for isolation and barrier nursing in patients with pneumonia	Clinical Posting			PA 7.5: Lab Diagnosis: Diagnostic workup including tumor markers..Spread, grading & staging.Tumor immunology(L)	PA 6.7 :Circulatory disturbances : Infarction, thrombosis, embolism, hyperemia, congestion & hemorrhage. ( DOAP) Batch A	PH 2.3 Demonstrate the appropriate setting up of an intravenous drip in a simulated environment Batch B ( Skill Lab)
17.3.22	Thurs	MI1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:General Virology (L)	Clinical Posting			MI 1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:General Parasitology (L)	Micro (DOAP )-MI 1.1:Describe the different causative agents of Infectious diseases+A208the methods used in their detection: ZN Staining (DOAP) Batch B CM 8.4, 8.5 (Batch A) Lymphatic Filariasis (SGT)	Micro (DOAP )-MI 1.1: Describe the different causative agents of Infectious diseases+A208the methods used in their detection:ZN Staining (DOAP) Batch B CM 8.4, 8.5 (Batch A) Yellow fever, JE (SGT)
18.3.22	Fri	PUBLIC HOLIDAY - HOLI				PUBLIC HOLIDAY - HOLI	PUBLIC HOLIDAY - HOLI	
19.3.22	3rd Sat	OG 8.2: (L) Elicit document and present an obstetric history including menstrual history, last menstrual period, previous obstetric history, comorbid conditions, past medical history and surgical history	9:30 – 10:30pm	MI 1.7: Describe the immunological mechanisms in health: Antiigen (L)	PH 1.23 Describe the process and mechanism of drug deaddiction ( seminar)	MI (SDL): ELISA (Extra)	Sports-	
			10:30- 11:30pm	Pharmac- 1.16 - (L) (Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs,) drugs for gout, anti-rheumatic drugs, drugs for migraine : 5-HT				
			11:30- 12:30pm	PATHO Test				



Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
21.3.22	Mon	CM 8.4, 8.5 Epidemiology of TB & Elimination (L)	Clinical Posting	Lunch	PH 1.15 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of skeletal muscle relaxants (L)	PA 6.7 :Circulatory disturbances : Infarction, thrombosis, embolism, hyperemia, congestion & hemorrhage. (DOAP) Batch B	PH 2.3 Demonstrate the appropriate setting up of an intravenous drip in a simulated environment Batch A ( Skill Lab)
22.3.22	Tues	OG 8.4: (L)Describe and demonstrate clinical monitoring of maternal and fetal well-being	Clinical Posting	Lunch	MII 1.9: Discuss the immunological basis of vaccines and describe the Universal Immunisation schedule: immunoprophylaxis (L)	PH 2.5 (SGT) Therapeutic Statergies inclding new drug development PANEDOMIC MODULE	P.A10.2Leishmaniasis, Filariasis, Hydatid, Cysticercosis(SGT) PH-(SGT) PH1.6 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs, drugs for migraine-Drugs for gout, anti-rheumatic drugs
23.3.22	Wed	MI 1.8:Describe the mechanisms of immunity and response of the host immune system to infections: CMI (L)	Clinical Posting	MI 1.8:Describe the mechanisms of immunity and response of the host immune system to infections: structure and function of Immune System (L)	MI 1.10: Describe the immunological mechanisms in immunological disorder (hypersensitivity, autoimmune disorders and immunodeficiency states) and discuss the laboratory methods used in detection.: Hypersensitivity (L)	Micro (DOAP )-MI 1.7 & 1.8: Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 2 (DOAP) Batch B CM 8.4, 8.5 (Batch B)Drancanculiasis. Trachoma SGT	Micro (DOAP )-MI 1.7 & 1.8: Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 2 (DOAP) Batch B CM8.4, 8.5 (Batch B) Leshmaniasis SGT

24.3.22	Thurs	MI 1.11: Describe the immunological mechanisms of transplantation and tumor immunity: Transplantaion Immunity (L)	Clinical Posting			MI 1.1: General Mycology (L)	Micro (DOAP )-MI 1.6:Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy: Diagnostic Micro 2 and Grams Staining (DOAP) Batch B, CM 8.4, 8.5 (Batch A) Infectious Disease Epidemiology (SGT )	Micro (DOAP )-MI 1.6:Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy: Diagnostic Micro 2 and Grams Staining (DOAP) Batch B, CM 8.4, 8.5 (Batch A) Infectious Disease Epidemiology (SGT )
25.3.22	Fri	SU 7.1 (L) Describe the Planning and conduct of Surgical audit SU 7.2 Describe the principles and steps of clinical research in General Surgery	Clinical Posting			PA9.4 Define autoimmunity. Enumerate autoimmune disorders. PA 9.5 Define and describe the pathogenesis of systemic Lupus Erythematosus (L)	PA 9.3 Describe the HLA system and the immune principles involved in transplant and mechanism of transplant rejection. ( seminar)	PH 1.18 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of general anaesthetics, and pre-anesthetic medications- GA (L)
26.3.22	3rd Sat	OG 8.3: (L) Describe, demonstrate, document and perform an obstetrical examination including a general and abdominal examination and clinical monitoring of maternal and fetal well-being;	9:30 – 10:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)	PH 1.17Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of local anesthetics- LA (SGT)	Patho Test	..	
			10:30-11:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)				
			11:30-12:30pm	PA 9.7: Common autoimmune diseases. (Tutorials) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm
28.3.22	Mon	CM 8.4, 8.5 Viral Hepatitis (L)	Clinical Posting		Lunch	(L) PH1.6 NSAIDS -I Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs, drugs for migraine	PA 23.1Urine Examination (DOAP)
29.3.22	Tues	FMT FM2.2 - Describe and discuss natural and unnatural deaths FM2.3 - Describe and discuss issues related to sudden natural deaths	Clinical Posting			(L) PH 1.6 NSAIDS-II Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs, drugs for migraine	Micro (DOAP )-MI 1.6:Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy  : Diagnostic Micro 2 and Grams Staining (DOAP) Batch A CM 8.4,8.5(Batch B) Leprosy. (SGT)
30.3.22	Wed	IM 3.17, 3.19: (AITO- Integrated)Describe and discuss the supportive therapy in patients with pneumonia including oxygen use and indications for ventilationDiscuss, describe, enumerate the indications and communicate to patients on pneumococcal and influenza vaccines	Clinical Posting			PA 13.1: describe hematopoiesis and medullary hematopoiesis	PA 23.1Urine Examination (DOAP)
31.3.22	Thurs	MI 1.7: Describe the immunological mechanisms in health: Immunity (L)	Clinical Posting			MI 1.7: Describe the immunological mechanisms in health: Antibody (L)	Micro (DOAP )-MI 1.6: ZN stain repeat (DOAP) Batch B CM 8.4,8.5(Batch B) Leprosy . (SGT)
1.4.22	Fri	SU 8.1 (L) Describe the principles of Ethics as it pertains to General Surgery SU 8.2 Demonstrate Professionalism and empathy to the patient undergoing General Surgery SU 8.3 Discuss medico legal issues in surgical practice	Clinical Posting			PA10.4Typhoid fever: Pathogenesis, morphology & clinical features. Syphilis: Classify various stages, pathogenesis & morphology.(L)	PA13.1Introduction to hematology & hemopoiesis(L)
2.4.22	4th Sat	PUBLIC HOLIDAY - GUDI PADWA			PUBLIC HOLIDAY - GUDI PADWA		
					PUBLIC HOLIDAY - GUDI PADWA		

3:30-4:30pm
Pharm (Batch B) PH 4.1 Administer drugs through various routes in a simulated environment using mannequins-Skill lab-Parenteral routes ( DOAP)
Micro (DOAP )-MI 1.6: Describe the mechanisms of drug resistance, and the methods of antimicrobial susceptibility testing and monitoring of antimicrobial therapy  : Diagnostic Micro 2 and Grams Staining (DOAP) Batch A CM 8.4,8.5 (Batch B) Nipah Virus. KFD. (SGT)
Pharm (Batch A) PH 4.1 Administer drugs through various routes in a simulated environment using mannequins-Skill lab-Parenteral routes ( DOAP)
Micro (DOAP )-MI 1.6: ZN stain repeat (DOAP) Batch B CM 8.4,8.5 (Batch B) Nipah Virus. KFD. (SGT)
PH- (SGT) PH1.6 Describe mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act by modulating autacoids, including: anti-histaminics, 5-HT modulating drugs, NSAIDs, drugs for gout, anti-rheumatic drugs, drugs for migraine- Anti-histaminics

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
4.4.22	Mon	CM 8.4,8.5 Poliomyelitis (L)		Clinical Posting	Lunch	PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) (L) OPIOID -I	PA 13.5PCV, ESR & Peripheral Smear Examination(DOAP) ( Batch A)	PH 2.4 ( Batch B) Demonstrate the correct method of calculation of drug dosage in patients including those used in special situations. PK -I ( DOAP)
5.4.22	Tues	FMT (L) FM2.4 - Describe salient features of the Organ Transplantation and The Human Organ Transplant (Amendment) Act 2011 and discuss ethical issues regarding organ donation FM2.5 - Discuss moment of death, modes of death - coma, asphyxia and syncope		Clinical Posting	Lunch	PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) (L) OPIOID -II	Micro (DOAP )-MI 1.6: ZN stain repeat (DOAP) Batch A CM 8.4, 8.5 (Batch A) Chikungunya. Leptospirosis, (SGT)	Micro (DOAP )-MI 1.6: ZN stain repeat (DOAP) Batch A CM 8.4, 8.5 (Batch B) Brucellosis. Plague., (SGT)
6.4.22	Wed	IM25.1: (L) Describe and discuss the response and the influence of host immune status, risk factors and comorbidities on zoonotic diseases (e.g. Leptospirosis, Rabies) and non-febrile infectious disease (e.g. Tetanus)		Clinical Posting		PA9.6AIDS: Epidemiology, etiopathogenesis.(L)	PA 13.5PCV, ESR & Peripheral Smear Examination(DOAP) ( Batch B)	PH 2.4 ( Batch A) Demonstrate the correct method of calculation of drug dosage in patients including those used in special situations. PK -I ( DOAP)
7.4.22	Thurs	MI 1.10: Describe the immunological mechanisms in immunological disorder (hypersensitivity, autoimmune disorders and immunodeficiency states) and discuss the laboratory methods used in detection.: Autoimmunity (L)		Clinical Posting		MI 1.7: Describe the immunological mechanisms in health: Immune Response (AMI)	Micro (DOAP )-MI 1.7 & 1.8: Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections Serological Reactions 1 (DOAP) Batch B CM 8.4, 8.5 (Batch A) Chikungunya. Leptospirosis, (SGT)	Micro (DOAP )-MI 1.7 & 1.8:Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections Serological Reactions 1 (DOAP) Batch B CM 8.4, 8.5 (Batch B) Brucellosis. Plague., (SGT)

8.4.22	Fri	SU 9.1 (L) Choose apprairate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in a surgical patient SU 9.2 Biological bases for early detection of cancer and multidisciplinary approach in management of cancer SU 9.3 Communicate the results of surgical investigations and council the patient appropriately	Clinical Posting			PA13.3PA13.4Anemia: classification and clinical features.(L)	PA10.1Parasitic: Malaria: Types, morphological features in P. Vivax & Falciparum Malaria & lab diagnosis.(integrated)	PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - Anxiolytic (SGT)
9.4.22	1st Sat	MI 8.1 Enumerate the microbial agents and their vectors causing Zoonotic diseases. Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: Yersinia (L)	9:30 – 10:30pm	PA 29.4 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the prostate	PH 1.43-Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Microbiology, Pediatrics, Medicine) INTEGRATED - Meningitis		sports	
			10:30- 11:30pm	PA 29.5 Describe the etiology, pathogenesis, pathology and progression of prostatitis (SGT)				
			11:30- 12:30pm	PH 1.43-Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Microbiology, Pediatrics, Medicine) INTEGRATED - Meningitis				

--	--	--	--	--	--	--	--	--

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
11.4.22	Mon	CM8.4, 8.5 Malaria (L)	Clinical Posting	Lunch	PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) -SEDATIVES (L)	PA 16.6 Prepare a peripheral blood smear and identify hemolytic anaemia from it . PS Staining ( DOAP)	PH 2.4 ( Batch B) Demonstrate the correct method of calculation of drug dosage in patients including those used in special situations. PK -I I ( DOAP)
12.4.22	Tues	FMT (L) FM 2.6 - Discuss presumption of death and survivorship FM 2.7 - Describe and discuss suspended animation	Clinical Posting		PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - ANTI- DEPRESSANTS L)	Micro (DOAP )-MI 1.7 & 1.8: Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 1 (DOAP) Batch A CM 8.4, 8.5 (Batch B)Drancanculiasis. Trachoma SGT	Micro (DOAP )-MI 1.7 & 1.8:Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 1 (DOAP) Batch A CM8.4, 8.5 (Batch B) Leshmaniasis SGT
13.4.22	Wed	IM 25.2, 25.3, 25.8: (L, SDL) Discuss and describe the common causes, pathophysiology and manifestations of these diseases. Describe and discuss the pathophysiology and manifestations of these diseases. Enumerate the indications for use of newer techniques in the diagnosis of these infections	Clinical Posting		PA14.1 Describe iron metabolism. PA14.2 Describe the etiology, investigations and differential diagnosis of microcytic hypochromic anemia	PA 16.6 Prepare a peripheral blood smear and identify hemolytic anaemia from it . PS Staining ( DOAP)	PH 2.4 ( Batch A) Demonstrate the correct method of calculation of drug dosage in patients including those used in special situations. PK -I I ( DOAP)
14.4.22	Thurs	public holiday - ambedkar jayanti			public holiday - ambedkar jayant	public holiday - ambedkar jayant	
15.4.22	Fri	SU 10.1 (L) Describe the principles of pre operative management of common surgical procedures SU 10.2 Describe the steps and obtain informed consent in a stimulated environment	Clinical Posting		PA 15.1 Describe the metabolism of Vitamin B12 and the etiology and pathogenesis of B12 deficiency. PA15.2 Describe laboratory investigations of macrocytic anemia	PA10.3Leprosy: Classify, pathogenesis, differentiate between different types of leprosy, histological features & sequelae.(integrated)	PH 1.25 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets, fibrinolytics, plasma expanders - plasma expanders and Rx of shock(SGT)



16.4.22	2nd Sat	OG 8.5: (L) Describe and demonstrate pelvic assessment in a model	9:30 – 10:30pm	M6.11:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Mycoplasma and Chlamydia (L)		PH 2.5 (SGT) Therapeutic Statergies inclding new drug development PANEDOMIC MODULE	Sports	
			10:30- 11:30pm	PH 1.25 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets, fibrinolytics- Coagulants and anticoagulants (L)				
			11:30- 12:30pm	PA 17.1 Enumerate the etiology, pathogenesis and findings in aplastic anemia PH 1.25 (SGT) Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs acting on blood, like anticoagulants, antiplatelets, fibrinolytics- Antiplatelets and fibrinolytics				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
18.4.22	Mon	CM 8.4,8.5 , HIV/AIDS (L)	Clinical Posting	Lunch	PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - ANTI PSYCHOTICS(L)	PA 14.3Peripheral smear findings in microcytic anemia and bone marrow aspiration DOAP	PH 4.2 Batch B Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning - Screening Techniques for New Drugs (DOAP)
19.4.22	Tues	FMT (L) FM2.8 - Describe and discuss postmortem changes including signs of death, cooling of body, post-mortem lividity, rigor mortis, cadaveric spasm, cold stiffening and heat stiffening FM 2.9 - Describe putrefaction, mummification, adipocere and maceration	Clinical Posting		PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - ANTI- EPILEPTICS(L)	Micro (DOAP )-MI 1.7 & 1.8:Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 2 (DOAP) Batch A CM8.4,8.5 (Batch B) New Infectious Disease	Micro (DOAP )-MI 1.7 & 1.8:Describe the immunological mechanisms in health Describe the mechanisms of immunity and response of the host immune system to infections : Serological Reactions 2 (DOAP) Batch A CM (Batch B) Hospital Acquired Infections
20.4.22	Wed	IM 4.8: (L) Discuss and describe the pathophysiology, aetiology and clinical manifestations of fever of unknown origin (FUO) including in a normal host, neutropenic host, nosocomial host and a host with HIV disease	Clinical Posting		PA16.1 Define and classify hemolytic anemia.PA16.2 Describe the pathogenesis and clinical features and hematologic indices of hemolytic anemia	PA 14.3Peripheral smear findings in microcytic anemia and bone marrow aspiration DOAP	PH 4.2 (Batch A) Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning - Screening Techniques for New Drugs (DOAP)
21.4.22	Thurs	MI 1.3: Infection (L)	Clinical Posting		MI 1.7: Describe the immunological mechanisms in healthComplement (L)	Micro (DOAP )-MI 3.8 Choose the appropriate laboratory test in the diagnosis of viral hepatitis with emphasis on viral markers: Diagnostic tests used in Virology (DOAP) Batch B CM8.4,8.5 (Batch A) New Infectious Disease	Micro (DOAP )-MI 3.8Choose the appropriate laboratory test in the diagnosis of viral hepatitis with emphasis on viral markers: Diagnostic tests used in Virology (DOAP) Batch B CM (Batch A) Hospital Acquired Infections

22.4.22	Fri	FMT (L) FM2.12 Describe the legal requirements to conduct post-mortem examination and procedures to conduct medico-legal post-mortem examination FM 2.13 - Describe and discuss obscure autopsy	Clinical Posting			(L) PH1.29 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure - Drugs for Heart failure	Micro (DOAP )-MI 2.3 Identify the microbial agents causing Rheumatic Heart Disease & infective Endocarditis: Streptococcus, Pneumococcus and Enterococcus (DOAP) Batch A CM 5.1, 5.2(Batch B)Assessment of Nutritional Status	Micro (DOAP )-MI 2.3: Identify the microbial agents causing Rheumatic Heart Disease & infective Endocarditis Streptococcus, Pneumococcus and Enterococcus (DOAP) Batch A CM 5.1, 5.2(Batch B) Nutritional Surveillance and Growth Monitoring (Batch B)
23.4.22	3 <sup>rd</sup> Sat	OG 8.6: (L) Assess and counsel a patient in a simulated environment regarding appropriate nutrition in pregnancy	9:30 – 10:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)		PA11.1Cytogenetic abnormalities and mutations in childhood.(SGT) PH 1.19 (SGT)Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - neurodegenerative disorders(SGT)	Sports	
			10:30- 11:30pm	AETCOM2.1: The foundations of communication – 2 (Patho) 2.5: Case studies on patient autonomy and decision making (Micro)				
			11:30- 12:30pm	PA11.1Cytogenetic abnormalities and mutations in childhood.(SGT) PH 1.19 (SGT)Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - neurodegenerative disorders(SGT)				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
25.4.22	Mon	CM8.4,8.5 Rabies (L)	Clinical Posting		Lunch	PH 1.35 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of drugs used in hematological disorders like: 1.D rugs used in anemias 2.Colony Stimulating factors- (Haematinics and Erythropoietin) (L)	PA 15.3Peripheral smear findings in macrocytic anemia & anemia Charts(DOAP)	PH 4.2 ( Batch B) Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning. PD-I ( DOAP)
26.4.22	Tues	FMT (L) FM2.10 - Discuss estimation of time since death FM 2.11 - Describe and discuss autopsy procedures including post-mortem examination, different types of autopsies, aims and objectives of post-mortem examination	Clinical Posting			PH 1.24 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs affecting renal systems including diuretics, antidiuretics- vasopressin and analogues. (Diuretics and antidiuretics) (L)	Micro (DOAP )-MI 3.8 Choose the appropriate laboratory test in the diagnosis of viral hepatitis with emphasis on viral markers: Diagnostic tests used in Virology (DOAP) Batch A CM8.4,8.5 (Batch B) Amoebiasis. Ascariasis. Hookworm. (SDL)	Micro (DOAP )-MI 3.8 Choose the appropriate laboratory test in the diagnosis of viral hepatitis with emphasis on viral markers: Diagnostic tests used in Virology (DOAP) Batch A CM (Batch B) Taeniasis. Hydatid Disease (SDL)
27.4.22	Wed	IM 4.16: (L)Enumerate the indications and describe the findings in tests of inflammation and specific rheumatologic tests, serologic testing for pathogens including HIV, bone marrow aspiration and biopsy	Clinical Posting			PA16.3Haemoglobinopathies: Thalassemia, Sickle cell anemia.(L)	PA 15.3Peripheral smear findings in macrocytic anemia & anemia Charts(DOAP)	PH 4.2 ( Batch A) Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning. PD-I ( DOAP)
28.4.22	Thurs	MI 1.11: Describe the immunological mechanisms of transplantation and tumor immunity: Tumour Immunity & IDD (L)	Clinical Posting			MI 2.2: Describe the classification etio-pathogenesis, clinical features and discuss the diagnostic modalities of Infective endocarditis: Streptococcus (L)	Micro (DOAP )-MI 2.3 Identify the microbial agents causing Rheumatic Heart Disease & infective Endocarditis: Streptococcus, Pneumococcus and Enterococcus (DOAP) Batch B CM8.4,8.5 (Batch A) Amoebiasis. Ascariasis. Hookworm. (SDL)	Micro (DOAP )-MI 2.3 Identify the microbial agents causing Rheumatic Heart Disease & infective Endocarditis: Streptococcus, Pneumococcus and Enterococcus (DOAP) Batch B CM (Batch A) Taeniasis. Hydatid Disease (SDL)
29.4.22	Fri	SU 10.3 (L) Observe common Surgical procedure and assist in minor surgical procedure observe emergency life saving surgical procedures SU 10.4 Perform basic surgical skill such as first aid including suturing and minor surgical procedure in stimulated environment.	Clinical Posting			PA18.2Acute leukemia: classification and diagnosis.Chronic leukemia: classification and diagnosis(L).	PA16.4: Describe the etiology pathogenesis, hematologic indices and peripheral blood picture of Acquired hemolytic anemia. PA16.5Describe the peripheral blood picture in different hemolytic anaemias	PH1.31 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in the management of dyslipidemias ( SGT)
			9:30 – 10:30pm	MI6.1:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Paramyxovirus (L)				

30.4.22	4th Sat	OG 8.7: (L) Enumerate the indications for and types of vaccination in pregnancy	10:30-11:30pm	PH 1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugs and drugs used in shock - Antihypertensive drugs (L)		Pandemic Module 2.2-Sample collection and Visit to lab Batch	Sports	
			11:30-12:30pm	PA11.2PA11.3Tumor and tumour- like conditions in infancy and childhood & Storage disorders in infancy and childhood (Seminar)				
				PH 1.26 Describe mechanisms of action, types, doses, side effects, indications and contraindications of the drugs modulating the renin- angiotensin and aldosterone system ( Drugs affecting renin- angiotensin and aldosterone system (SGT)				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
2.5.22	Mon	CM 5.3 Nutritional Problems in Public Health (L)	Clinical Posting		Lunch	(L)-PH1.29 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure Cardiac glycosides	PA18.1& 18.2 Total WBC Count / Leukemias/ Leucocytosis, leucopenia, Leukemoid reaction(DOAP)	PH 4.2 ( Batch B) Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning. PD-II ( DOAP)
3.5.22	Tues	PUBLIC HOLIDAY - RAMZAN EID				PUBLIC HOLIDAY - RAMZAN EID	PUBLIC HOLIDAY - RAMZAN EID	
4.5.22	Wed	IM 4.18: (L, SDL) Enumerate the indications for use of imaging in the diagnosis of febrile syndromes	Clinical Posting			PA21.1PA21.2Hemorrhagic disorders: Classify and lab. Screening tests for hemorrhagic disorders. Platelet deficiency, ITP & hemophilia(L)	PA18.1 & 18.2 Total WBC Count / Leukemias/ Leucocytosis, leucopenia, Leukemoid reaction(DOAP)	PH 4.2 ( Batch A) Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning. PD-II ( DOAP)
5.5.22	Thurs	MI 2.2: Describe the classification etio-pathogenesis, clinical features and discuss the diagnostic modalities of Infective endocarditis: Pneumococcus and Enterococcus (L)	Clinical Posting			MI 2.4:List the common microbial agents causing anemia. Describe the morphology, mode of infection and discuss the pathogenesis, clinical course diagnosis and prevention and treatment of the common microbial agents causing Anemia: Dengue and Chickungunya (L)	Micro (DOAP )-MI 2.6Identify the causative agent of malaria and filariasis: Blood Protozoa (DOAP) Batch B CM 5.1, 5.2(Batch B) Assessment of Nutritional Status	Micro (DOAP )-MI 2.6 Identify the causative agent of malaria and filariasis: Blood Protozoa (DOAP) Batch B CM 5.1, 5.2(Batch B) Nutritional Surveillance and Growth Monitoring (Batch B)
6.5.22	Fri	SU 11.5 (L) Describe principles of providing post operative pain relief and management of chronic in SU 11.6 Describe principles of safe general surgery	Clinical Posting			PA21.3 Differentiate platelet from clotting disorders based on the clinical and hematologic features.	PA22.1Classify and describe blood group systems (ABO and RH).	PH 1.27 (SGT)-Integrated Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugsand drugs used in shock-Hypertension
7.5.22	5th Sat	OG 8.8: (L) Enumerate the indications and describe the investigations including the use of ultrasound in the initial assessment and monitoring in pregnancy	9:30 – 10:30pm	AETCOM2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication – 2 (Patho)	(L) PH1.29 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure - Antianginal -I	Micro 1st IA MCQ Test	Sports	
			10:30-11:30pm	AETCOM2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication – 2 (Patho)				
			11:30-12:30pm	PA 16.7 Discribe the correct technique to perform a cross match				
				(SGT) PH1.27-Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugsand drugs used in shock-Integrated (MI)				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
9.5.22	Mon	CM 5.3, 5.6Food Borne Diseases (L)	Clinical Posting		Lunch	(L) PH1.29 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure - Antianginal -II	PA 22.2 Blood group estimation & Demonstration of Cross match (DOAP)	PH 4.2 (Batch B): Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning-CAL-1
10.5.22	Tues	FMT revision	Clinical Posting			PH1.30 L Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the antiarrhythmics -Antiarrhythmic drugs	Micro (DOAP )-MI 2.6Identify the causative agent of malaria and filariasis: Blood Protozoa (DOAP) Batch A CM 5.1,5.4(Batch B) Food Surveillance	Micro (DOAP )-MI 2.6 Identify the causative agent of malaria and filariasis: Blood Protozoa (DOAP) Batch A CM 5.1,5.4(Batch B) Food Additives and Food Fortification
11.5.22	Wed	IM 6.1, 6.2 (L) : Describe and discuss the symptoms and signs of acute HIV seroconversion. Define and classify HIV AIDS based on the CDC criteria	Clinical Posting			PA22.4Blood Components & Autologous Transfusion(L)	PA 22.2 Blood group estimation & Demonstration of Cross match (DOAP)	PH 4.2 (Batch A): Demonstrate the effects of drugs on blood pressure (vasopressor and vaso-depressors with appropriate blockers) using computer aided learning-CAL-1
12.5.22	Thurs	MI 2.5:Describe the etio-pathogenesis and discuss the clinical evolution and the laboratory diagnosis of kalaazar, malaria, filariasis and other common parasites prevalent in India: Filaria (L)	Clinical Posting			MI 2.7:Describe the epidemiology, the etio- pathogenesis, evolution complications, opportunistic infections, diagnosis, prevention and the principles of management of HIV: HIV (L)	Micro (DOAP )-MI 4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Mycology Micro (DOAP )- MI 8.10: Demonstrate the appropriate method of collection of samples in the performance of laboratory tests in the detection of microbial agents causing Infectious diseases: collection of samples and Medical Entomology (DOAP) (DOAP) Batch A ) CM 5.1,5.4(Batch B) Food Surveillance	Micro (DOAP )-MI 4.3Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Mycology Micro (DOAP )- MI 8.10: Demonstrate the appropriate method of collection of samples in the performance of laboratory tests in the detection of microbial agents causing Infectious diseases: collection of samples and Medical Entomology (DOAP) Batch A ) CM 5.1,5.4(Batch B) Food Additives and Food Fortification
13.5.22	Fri	SU 12.1 (L) Enumerate the causes and consequences of mal nutrition in the Surgical patients SU 12.2 Describe and discuss methods of estimation and replacement of the fluid and electrolyte requirement in surgical patients SU 12.3 Discuss the nutritional requirement of surgical patients, the methods of providing nutritional support and their complications	Clinical Posting			PA22.6Blood transfusion: Indications, selection of donor criteria, cross matching, untoward reactions.(L)	PA22.7Autologous transfusion(Small group discussion)	Pharm -SDL Intro to Sympathetic system
14.5.22	1st Sat	OG 9.1.: (L) Classify, define and discusses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic	9:30 – 10:30pm	AETCOM2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication – 2 (Patho)		CM Extra	Sports	
			10:30-11:30pm	AETCOM2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication – 2 (Patho)				

			11:30-12:30pm	PA 22.5 Enumerate and describe infections transmitted by blood transfusion				
				Pharm-SDL Ph 1.14 General consideration of parasympathetic system				



1st TERMINAL EXAM FROM 16th May to 30th May 2022

Theory			
Date	Day	Time	Subject
16.5.22	Mon	1-4 pm	Patho
17.5.22	Tues	1-4 pm	Micro
18.5.22	Wed	1-4 pm	Pharmac
19.5.22	Thurs	1-4 pm	FMT
20.5.22	Fri	1-4 pm	CM
21.5.22	Sat	9:30 to 12:30pm	Medicine
23.5.22	Mon	1-4 pm	Surgery
24.5.22	Tues	1-4 pm	OBGYN

Practicals: 1:00 pm onwards (Batches A to E)					
2452	Patho	Micro	Pharm	FMT	CM
25.5.22	A	B	C	D	E
26.5.22	E	A	B	C	D
27.5.22	D	E	A	B	C
28.5.22	C	D	E	A	B
30.5.22	B	C	D	E	A

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
31.5.22	Tues	SU22.2 (L) Describe the etiopathogenesis of thyroidal swellings	Clinical Posting			CM Role of Nutrients in Health (SDL)	PA 23.3 Thyroid function tests, renal function tests, liver function tests & semen analysis (DOAP)	PH 2.1 (Batch A) Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)- Pharmacy (Solution, Suspension, Emulsion)
1.6.22	Wed	IM 6.5, 6.6:(AITO- Integrated) Describe and discuss the pathogenesis, evolution and clinical features of common HIV related malignancies. Describe and discuss the pathogenesis, evolution and clinical features of common HIV related skin and oral lesions	Clinical Posting			PA24.1Precancerous lesions of oral cavity and oral cancers: etiopathogenesis, gross and microscopic features. Differential diagnosis of swelling of salivary gland.(L)	MI3.1: Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Enterobacteriaceae (DOAP) Batch A	Pharm-PH1.34 (Anti- diarrhoeal) ) Lecture Acid-peptic disease andGERD—Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease andGERD 2. Antiemetics and prokinetics 3. Antidiarrhoeals4.Laxatives 5. Inflammatory BowelDisease 6. Irritable Bowel Disorders, biliary and pancreaticdiseases (INTEGRATED )
2.6.22	Thurs	MI 2.7 Describe the epidemiology, the etio- pathogenesis, evolution complications, opportunistic infections, diagnosis, prevention and the principles of management of HIV: HIV (Integrated)	Clinical Posting			Pharm-PH1.34 (Peptic ulcer ) Lecture Acid-peptic disease andGERD—Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease andGERD 2. Antiemetics and prokinetics 3. Antidiarrhoeals4.Laxatives 5. Inflammatory BowelDisease 6. Irritable Bowel Disorders, biliary and pancreaticdiseases (L)	PA23.2Describe abnormal findings in body fluids in various disease states FMT	PA23.2Describe abnormal findings in body fluids in various disease states FMT
3.6.22	Fri	OG 9.3: (L) Classify, define and discusses the aetiology and management of abortions including threatened, incomplete, inevitable, missed and septic Describe the steps and observe/ assist in the performance of an MTP evacuation	Clinical Posting			MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Ecoli, Klebsiella Proteus (L)	PA12.1 Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol, PA 12.2Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation (SGT)	FMT
4.6.22	1st Sat	AETCOM 2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication	9:30 – 10:30am	AETCOM2.5: Case studies on patient autonomy and decision making (Micro) 2.1: The foundations of communication – 2 (Patho)	MI3.1: Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Enterobacteriaceae (DOAP) Pharm-PH1.34 SGT-Integrated (Purgatives & Laxatives ) Acid-peptic disease andGERD—Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs used as below: 1. Acid-peptic disease andGERD 2. Antiemetics and prokinetics 3. Antidiarrhoeals4.Laxatives 5. Inflammatory BowelDisease 6. Irritable Bowel Disorders, biliary and pancreaticdiseases	Sports	-	-
			10:30-11:30am	PA 24.2Describe the etiology, pathogenesis, pathology, microbiology, clinical and microscopic features of peptic ulcer disease. (L)				

		– 2 (Patho)	11:30-12:30pm	MI3.1: Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Enterobacteriaceae (DOAP)	(INTEGRATED)			
--	--	-------------	---------------	---	--------------	--	--	--

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
6.6.22	Mon	MI 3.1: Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Vibrio (L)	Clinical Posting		Lunch	PH 1.36 (L) Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)-INSULIN	PA24.3Alimentary System DOAP Batch A	PH 2.1 (Batch B)Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)-Pharmacy (Ointment. Lotion, Linniment)
7.6.22	Tues	SU28.8 (L) Describe and discuss the aetiology, the clinical features, K investigations and principles of management of congenital <sup>[1]</sup> hypertrophic pyloric stenosis, Peptic ulcer disease, Carcinoma <sup>[1]</sup> stomach	Clinical Posting			CM 3.1 Air & Health (L)	PA24.3Alimentary System DOAP Batch B	PH 2.1 (Batch A)Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)-Pharmacy (Ointment. Lotion, Linniment) (DOAP)
8.6.22	Wed	IM 6.16, 6.17, 6.18: Discuss and describe the principles of HAART, the classes of antiretrovirals used, adverse reactions and interactions. Discuss and describe the principles and regimens used in post exposure prophylaxis. Enumerate the indications and discuss prophylactic drugs used to prevent HIV related opportunistic infections	Clinical Posting			PA24.4Tumors of upper Gastrointestinal Tract: Gastric carcinoma: etiopathogenesis, classification, gross and microscopic features and clinical features. Carcinoid tumors of GIT Esophagus: etiopathogenesis, morphology and clinical features.(L)	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Vibrio and shigella (DOAP) Batch A	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Vibrio and shigella (DOAP) Batch A PH 1.36 (L) Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)-DIABETES ( INTEGRATED)
9.6.22	Thurs	MI 3.6Describe the etio-pathogenesis of Acid peptic disease (APD) and the clinical course. Discuss the diagnosis and management of the causative agent of APD: H pylori, Campylobacter, CI difficile (L)	Clinical Posting			PH 1.36(L) Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)-OHA	PA24.5Describe and etiology and pathogenesis and pathologic features of Tuberculosis of the intestine (L)	FMT (lect) FM2.22 - Mechanical asphyxia: Describe and discuss patho-physiology, clinical features, postmortem findings and medico-legal aspects of traumatic asphyxia, obstruction of nose & mouth, suffocation and sexual asphyxia FM2.23 - Describe and discuss types, patho-physiology, clinical features, postmortem findings and medico-legal aspects of drowning, diatom test and, gettler test.
10.6.22	Fri	OG 10.1: (L) Define, classify and describe the aetiology, pathogenesis, clinical features, ultrasonography, differential diagnosis and management of antepartum haemorrhage in pregnancy.	Clinical Posting			MI 3.1 Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Ascaria, Hookworm, Trichuris, E Vermicularis, strongyloides (L)	PA24.6Idiopathic inflammatory bowel disease: etiopathogenesis, morphology and differences between Crohn’s disease and ulcerative colitis .Appendicitis(L)	FMT FM2.27 - Define and discuss infanticide, foeticide and stillbirth FM2.28 - Describe and discuss signs of intrauterine death, signs of live birth, viability of foetus, age determination of foetus, DOAP session of ossification centres, Hydrostatic test, Sudden Infants Death syndrome and Munchausen’s syndrome by proxv
			9:30 – 10:30am	CM 3.1 Air & Health (L)				
			10:30-11:30pm	PA 24.7Describe the etiology, pathogenesis, pathology and distinguishing features of carcinoma of the colon (L)				

11.6.22	2nd sat	IM 15.3, 15.11, 15.12:(AITO- Integrated) Describe and discuss the physiologic effects of acute blood and volume loss. Develop, document and present a treatment plan that includes fluid resuscitation, blood and blood component transfusion, and specific therapy for arresting blood lossEnumerate the indications for whole blood, component and platelet transfusion and describe the clinical features and management of a mismatched transfusion.	.30am -12.30p	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Vibrio and shigella (DOAP) Batch B Pharm (Batch B)-	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Vibrio and shigella (DOAP) Batch B PH 1.36 (L) Describe the mechanism of action, types, doses, side effects, indications and contraindications of drugs used in endocrine disorders (diabetes mellitus, thyroid disorders and osteoporosis)- Hormones and Drugs affecting calcium balance (SGT)			
---------	---------	--	---------------	--	--	--	--	--

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
13.6.22	Mon	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: E Histolytica (L)	Clinical Posting		PH 1.37 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones - Introduction & Anterior Pituitary hormones (L)	PA:8.3 Cytology and stains - Batch A( DOAP )	PH 2.1 (Batch B)Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)-Pharmacy (ORS) DOAP
14.6.22	Tues	SU15.1 (L) Describe classification of hospital waste and appropriate methods of Disposal	Clinical Posting		CM 3.4 Disposal of Waste ( Solid & Excreta) (L)	PA:8.3 Cytology and stains Batch B (DOAP)	PH 2.1 (Batch A)Demonstrate understanding of the use of various dosage forms (oral/local/parenteral; solid/liquid)-Pharmacy (ORS) DOAP
15.6.22	Wed	IM 15.1, 15.2:(L, SDL) Enumerate, describe and discuss the aetiology of upper and lower GI bleeding. Enumerate, describe and discuss the evaluation and steps involved in stabilizing a patient who presents with acute volume loss and GI bleed	Clinical Posting		PA 25.1 Describe bilirubin metabolism, enumerate the etiology and pathogenesis of jaundice, distinguish between direct and indirect hyperbilirubinemia	MI3.4 Identify the different modalities for diagnosis of enteric fever. Choose the appropriate test related to the duration of illness: Salmonella (DOAP) (DOAP) Batch A	MI3.4 Identify the different modalities for diagnosis of enteric fever. Choose the appropriate test related to the duration of illness: Salmonella (DOAP)(DOAP) Batch A / Pharmac (Batch B) PH 1.23 Describe the process and mechanism of drug deaddiction- Drug addiction & Over Dose Toxicity (SEMINAR)
16.6.22	Thurs	MI 3.1Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Taenia (L)	Clinical Posting		PH 1.37 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones -Estrogens & anta (L)	PA 25.2 Describe the pathophysiology and pathologic changes seen in hepatic failure and their clinical manifestations, complications and consequences	FMT (L) FM 2.25 - Describe and discuss clinical features, post-mortem findings and medico-legal aspects of death due to starvation and neglect FM 2.26 - Describe and discuss clinical features, post-mortem findings and medico-legal aspects of death due to starvation and neglect

17.6.22	Fri	OG 10.2: (L) Enumerate the indications and describe the appropriate use of blood abd blood products, their complications and management	Clinical Posting			MI3.1:Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Shigella (SG)	PA25.3Viral hepatitis: Etiopathogenesis, types, clinical source, pathology, serologic diagnosis, sequelae.(L)	FMT FM2.30 - Have knowledge/awareness of latest decisions/notifications/resolutions/circulars/standing orders related to medico-legal practice issued by Courts/Government authorities etc
18.6.22	3rd Sat	AETCOM 2.6: Case studies on patient autonomy and decision making (Patho) 2.7: Case studies on patient autonomy and decision making (Pharmac)	9:30 – 10:30pm	AETCOM2.6: Case studies on patient autonomy and decision making (Patho) 2.7: Case studies on patient autonomy and decision making (Pharmac)	MI3.4 Identify the different modalities for diagnosis of enteric fever. Choose the appropriate test related to the duration of illness: Salmonella (DOAP) Batch B PH1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugsand drugs used inshock (HT) Seminar	Sports	-	-
			10:30- 11:30pm	PA25.4Alcoholic liver disease: Pathogenesis, morphology and correlation with clinical features.(L)				
			11:30- 12:30pm	MI3.4 Identify the different modalities for diagnosis of enteric fever. Choose the appropriate test related to the duration of illness: Salmonella (DOAP) Batch B				
				PH1.27 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of antihypertensive drugsand drugs used inshock (HT) Seminar				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
20.6.22	Mon	MI 3.3., 3.5:Describe the enteric fever pathogens and discuss the evolution of the clinical course and the laboratory diagnosis of the diseases caused by them Enumerate the causative agents of food poisoning and discuss the pathogenesis, clinical course and laboratory diagnosis : Enteric fever and Non typhoidal salmonella (L)	Clinical Posting		PH 1.37 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used as sex hormones, their analogues and anterior Pituitary hormones -Progestins & antagonists (L)	PA 19.5Hodgkin's lymphoma in a gross and microscopic specimen, PA 19.3 Lymphnode (DOAP)	PH3.1 (Batch B) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- Single drug therapy (DOAP)
21.6.22	Tues	SU9.1 (L) Choose appropriate biochemical, microbiological, pathological, imaging investigations and interpret the investigative data in a surgical patient	Clinical Posting		CM: Environment Helath (SDL)	PA 19.5Hodgkin's lymphoma in a gross and microscopic specimen, PA 19.3 Lymphnode (DOAP)(Batch B)	PH3.1 (Batch A) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- Single drug therapy (DOAP)
22.6.22	Wed	IM 15.6, 15.10, 15.16: (AITO- Integrated)Distinguish between upper and lower gastrointestinal bleeding based on the clinical features. Enumerate the indications for endoscopy, colonoscopy and other imaging procedures in the investigation of Upper GI bleeding. Enumerate the indications for endoscopic interventions and Surgery	Clinical Posting			MI3.1:Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Intestinal Nematodes and stool examination(DOAP) Batch A	MI3.1:Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Intestinal Nematodes and stool examination(DOAP) Batch A PH 1.28 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in ischemic heart disease (stable, unstable angina and myocardial infarction), peripheral vascular disease (Angina- SEMINAR)



23.6.22	Thurs	MI 3.7: Describe the epidemiology, the etio-pathogenesis and discuss the viral markers in the evolution of Viral hepatitis. Discuss the modalities in the diagnosis and prevention of viral hepatitisHepatitis (Integrated)	Clinical Posting		PH1.39 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception - OC pills (L)	PA25.1Jaundice(Integrated)	FMT FM2.29 (DOAP) Batch A - Demonstrate respect to the directions of courts, while appearing as witness for recording of evidence under oath or affirmation, examination in chief, cross examination, re-examination and court questions, recording of evidence
24.6.22	Fri	OG 11.1: (L) Describe the etiopathology, clinical features; diagnosis and investigations, complications, principles of management of multiple pregnancies	Clinical Posting		MI 3.5 Enumerate the causative agents of food poisoning and discuss the pathogenesis, clinical course and laboratory diagnosis: Food poisoning (Integrated)	PA26.2Lung abscess: Etiopathogenesis, Morphology and complications.and atelectasis and hyaline membrane disease.  Tutorials	FMT FM2.29 (DOAP) Batch A - Demonstrate respect to the directions of courts, while appearing as witness for recording of evidence under oath or affirmation, examination in chief, cross examination, re-examination and court questions, recording of evidence
25.6.22	4 <sup>th</sup> Sat	FMT FM 2.24 -Thermal deaths: Describe the clinical features, post-mortem finding and medicolegal aspects of injuries due to physical agents like heat (heat-hyper-pyrexia, heat stroke, sun stroke, heat exhaustion/prostration, heat cramps [miner's cramp] or cold (systemic and localized hypothermia, frostbite, trench foot, immersion foot)	9:30 – 10:30pm	CM Occupational Diseases. Pnumoconiasis (L)	MI3.1:Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Intestinal Nematodes and stool examination (DOAP) Batch B/ PH 1.29Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in congestive heart failure ( SEMINAR- CCF)	Sports	-
			10:30- 11:30pm	PA25.5Cirrhosis: Etiopathogenesis, classification, pathology, complications & differential diagnosis & Portal Hypertension(L)			
			11:30- 12:30pm	MI3.1: Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Intestinal Nematodes and stool examination (DOAP) Batch B			

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
27.6.22	Mon	MI 3.7: Describe the epidemiology, the etio-pathogenesis and discuss the viral markers in the evolution of Viral hepatitis. Discuss the modalities in the diagnosis and prevention of viral hepatitis: Liver fluke (SG)	Clinical Posting		PH 1.40 Describe mechanism of action, types, doses, side effects, indications and contraindications of 1. Drugs used in the treatment of infertility, and 2. Drugs used in erectile dysfunction - Androgens and Erectile Dysfunction (L)	PA 25.6 Hepatobiliary SystemDOAP( Batch A)	PH3.1 (Batch B) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- Multi drug therapy (DOAP)
28.6.22	Tues	SU28.10 (L) Describe the applied anatomy of liver. Describe the clinical features, Investigations and principles of management of liver abscess, hydatid disease, injuries and tumors of the liver	Clinical Posting		Prevention of Occupational Diseases. ESI Act. (L)	PA 25.6 Hepatobiliary SystemDOAP (Batch B)	PH3.1 (Batch A) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- Multi drug therapy (DOAP)
29.6.22	Wed	IM 15.14, 15.15:(L, SDL)Describe and enumerate the indications, pharmacology and side effects of pressors used in the treatment of Upper GI bleed.Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy of acid peptic disease including Helicobacter pylori	Clinical Posting		PA26.3Chronic obstructive pulmonary disease: Bronchial asthma and Bronchiectasis - Etiopathogenesis, Morphology and complications.(L)	MI 3.2: Identify the common etiologic agents of diarrhea and dysentery: Intestinal Protozoa and stool Examination(DOAP) Batch A	MI 3.2: Identify the common etiologic agents of diarrhea and dysentery: Intestinal Protozoa and stool Examination(DOAP) Batch A / PH 1.19 escribe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs)- Treatment of Epilepsy (SEMINAR)
30.6.22	Thurs	MI 3.1:Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Giardia (Sem)	Clinical Posting		PH1.38 Describe the mechanism of action, types, doses, side effects, indications and contraindications of corticosteroids (Corticosteroids) (L) Part-I	PA26.2Lung abscess: Etiopathogenesis, Morphology and complications.and atelectasis and hyaline membrane disease. Tutorials	FMT (Batch A)

1.7.22	Fri	OG 12.1: (L) Define, classify and describe the etiology and pathophysiology,early detection, investigations; principles of management of hypertensive disorders of pregnancy and eclampsia, complications of eclampsia	Clinical Posting			MI 6.1: Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: C diptheriae (L)	PA26.4Pulmonary tuberculosis: primary and secondary, morphologic types including pleuritis, clinical course.(Integrated)	FMT (Batch B)
2.7.22	1st Sat	FMT FM 2.31 - Demonstrate ability to work in a team for conduction of medico-legal autopsies in cases of death following alleged negligence medical dowry death, death in custody or following violation of human rights as per National Human Rights Commission Guidelines on exhumation	9:30 – 10:30pm	Family Planning & MTP Act (L)	MI 3.2:Identify the common etiologic agents of diarrhea and dysentery: Intestinal Protozoa and stool Examination (DOAP) Batch B/PH 1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti-depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) - Parkinson’s disease SEMINAR	Sports	-	-
			10:30- 11:30pm	PA26.5Occupational lung disorders: Anthracosis, silicosis, asbestosis, mesothelioma.(L)				
			11:30- 12:30pm	MI 3.2: Identify the common etiologic agents of diarrhea and dysentery: Intestinal Protozoa and stool Examination (DOAP) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
4.7.22	Mon	MI 3.1 Enumerate the microbial agents causing diarrhea and dysentery. Describe the epidemiology, morphology, pathogenesis, clinical features and diagnostic modalities of these agents: Isospora, Cryptospora (Sem)	Clinical Posting		PH1.38 Describe the mechanism of action, types, doses, side effects, indications and contraindications of corticosteroids (Corticosteroids) Part -II (L)	PA26.1Respiratory SystemDOAP	PH3.1 (Batch B) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- FDC (DOAP)
5.7.22	Tues	SU17.1 (L) Describe the Principles of FIRST AID	Clinical Posting		CM: Calculation of Demographic Indicators (SDL)	PA26.1Respiratory SystemDOAP	PH3.1 (Batch A) Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient- FDC (DOAP)
6.7.22	Wed	IM 16.1, 16.2, 16.3, 16.6: (L) Describe and discuss the aetiology of acute and chronic diarrhea including infectious and non infectious causes. Distinguish between diarrhea and dysentery based on clinical features. Describe and discuss the acute systemic consequences of diarrhea including its impact on fluid balance. Describe and discuss the chronic effects of diarrhea including malabsorption	Clinical Posting		PA 26.6Define and describe the etiology, types, exposure, genetics environmental influence, pathogenesis, stages, morphology, microscopic appearance,metastases and complications of tumors of the lung and pleura	MI 6.3:Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain): M tuberculosis and ZN staining (Cerification)(DOAP) Batch A	MI 6.3:Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain): M tuberculosis and ZN staining (Cerification)(DOAP) Batch A PH5.1 Communicate with the patient with empathy and ethics on all aspects of drug use (Medicine) INTEGRATED-BIOETHICS -I
7.7.22	Thurs	MI 6.1: Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: M tuberculosis (L)	Clinical Posting		PH 1.41 Describe the mechanisms of action, types, doses, side effects, indications and contraindications of uterine relaxants and stimulants- Oxytocin and Other Drugs acting on Uterus (L)	PA26.7Complications of mesothelioma (Integrated)	FMT (L) FM 2.34 - Demonstrate ability to use local resources whenever required like in mass disaster situations

8.7.22	Fri	OG 12.2: (L) Define, classify and describe the etiology, pathophysiology, diagnosis, investigations, adverse effects on the mother and foetus and the management during pregnancy and labor, and complications of anemia in pregnancy.	Clinical Posting			MI 2.1 Describe the etiologic agents in rheumatic fever and their diagnosis: Causative agents of Rheumatic fever and its diagnosis (Integrated)	PA27.1Atherosclerosis: Definition, etiopathogenesis, gross and microscopic features, complications and clinical correlation(L)	FMT (L )FM 2.34 - Demonstrate ability to use local resources whenever required like in mass disaster situations
9.7.22	1st Sat	AETCOM2.6: Case studies on patient autonomy and decision making (Patho) 2.7: Case studies on patient autonomy and decision making (Pharmac)	9:30 – 10:30pm	AETCOM2.6: Case studies on patient autonomy and decision making (Patho) 2.7: Case studies on patient autonomy and decision making (Pharmac)	MI 6.3: Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain): M tuberculosis and ZN staining (Cerification) (DOAP) Batch B  PH5.1 Communicate with the patient with empathy and ethics on all aspects of drug use (Medicine) INTEGRATED- BIOETHICS -I	AETCOM2.6: Case studies on patient autonomy and decision making (Patho) 2.7: Case studies on patient autonomy and decision making (Pharmac)	Sports	-
			10:30-11:30pm	PA27.2 Other diseases of blood vessels : Aneurysms & Vasculitis				
			11:30-12:30pm	MI 6.3:Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain): M tuberculosis and ZN staining (Cerification) (DOAP) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
11.7.22	Mon	MI 6.1Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Atypical Mycobacteria (L)	Clinical Posting			PH1.42 (L) Describe general principles of chemotherapy	PA 19.7Gross specimen of an enlarged spleen DOAP(Batch A)	PH3.2 Perform and interpret a critical appraisal (audit) of a given prescription- Criticism of prescription ( Batch B)(DOAP)
12.7.22	Tues	SU27.1 (L) Describe the etiopathogenesis, clinical features, investigations and principles of treatment of occlusive arterial disease.  SU27.2 Demonstrate the correct examination of the vascular system and enumerate and describe the investigation of vascular disease	Clinical Posting			Dietary Advice - I (SDL)	PA 19.7Gross specimen of an enlarged spleen DOAP(Batch B)	PH3.2 Perform and interpret a critical appraisal (audit) of a given prescription- Criticism of prescription ( Batch A)(DOAP)
13.7.22	Wed	IM 16.11, 16.12: (L) Enumerate the indications for stool cultures and blood cultures in patients with acute diarrhea.Enumerate and discuss the indications for further investigations including antibodies, colonoscopy, diagnostic imaging and biopsy in the diagnosis of chronic diarrhea	Clinical Posting			PA27.3 Heart failure Integrated	MI 6.2 , 6.3:Identify the common etiologic agents of upper respiratory tract infections (Gram Stain) Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) : C diphtheria and albert staining Certification(DOAP) Batch A	MI 6.2 , 6.3:Identify the common etiologic agents of upper respiratory tract infections (Gram Stain) Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) : C diphtheria and albert staining Certification(DOAP) Batch A / PH5.1 Communicate with the patient with empathy and ethics on all aspects of drug use (Medicine) INTEGRATED- BIOETHICS -II
14.7.22	Thurs	MI 6.1Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Bordatella (L)	Clinical Posting			PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Penicillins) (L)	PA27.5Ischemic heart disease: Categories and pathogenesis. Myocardial infarction : incidence, risk factors, pathogenesis, morphology, complications, clinical course and investigations (SGT)	Patho (Batch B) FMT (Batch A) FMT L - FM2.33 - Demonstrate ability to use local resources whenever required like in mass disaster situations
15.7.22	Fri	OG (L) 13.1.1 and 13.1.4Enumerate and discuss the physiology of normal labour, mechanism of labor in occipito anterior presentation monitoring of labour including partogram conduct of labour	Clinical Posting			MI 2.2: Describe the classification etio-pathogenesis, clinical features and discuss the diagnostic modalities of Infective endocarditis: Classification etio pathogenesis, clinical features and diagnostic modalities of Infective Endocarditis (Sem)	PA27.9 Classify and describe the etiology, types, pathophysiology, pathology, gross and microscopic features, diagnosis and complications of cardiomyopathies (SGT)	Patho (Batch A) FMT (Batch B)FM2.33 - Demonstrate ability to use local resources whenever required like in mass disaster situation
16.7.22	2nd Sat	FMT FM 2.32 - Demonstrate ability to exchange information by verbal, or nonverbal communication to the peers, family members, law enforcing agency and judiciary	9:30 – 10:30pm	CM Revision Class	MI 6.2 , 6.3:Identify the common etiologic agents of upper respiratory tract infections (Gram Stain) Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) : C diphtheria and albert staining Certification (DOAP) Batch A PH5.1 (SGT) Communicate with the patient with empathy and ethics on all aspects of drug use (Medicine) INTEGRATED- BIOETHICS -II	Sports	-	-
			10:30- 11:30pm	PA27.4Rheumatic heart disease: Incidence, etiology, Pathogenesis, morphology, complications, clinical course & investigations.(L)				
			11:30- 12:30pm	MI 6.2 , 6.3:Identify the common etiologic agents of upper respiratory tract infections (Gram Stain) Identify the common etiologic agents of lower respiratory tract infections (Gram Stain & Acid fast stain) : C diphtheria and albert staining Certification (DOAP) Batch A				
	PH5.1 (SGT) Communicate with the patient with empathy and ethics on all aspects of drug use (Medicine) INTEGRATED- BIOETHICS -II							

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
18.7.22	Mon	MI 6.1:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: lung fluke (Sem)	Clinical Posting			PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Cephalosporins & other beta lactums) (L)	27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes ( DOAP) Batch A	PH 3.3 Perform a critical evaluation of the drug promotional literature ( DOAP) Batch- B
19.7.22	Tues	SU29.3 Describe the Clinical features, Investigations and principles of management of urinary tract infections	Clinical Posting	Lunch		Dietary Advice - II (SDL)	27.8 Interpret abnormalities in cardiac function testing in acute coronary syndromes ( DOAP	PH 3.3 Perform a critical evaluation of the drug promotional literature ( DOAP) Batch- A
20.7.22	Wed	IM 16.13, 16.14:(L) Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy for parasitic causes of diarrhea.Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy for bacterial and viral diarrhea	Clinical Posting			PA27.6Infective endocarditis: Causes, Pathogenesis, morphology, complications and differential diagnosis of cardiac vegetations.L	MI6.2, 6.3: Bordatella and Hemophilus (DOAP) Batch A + PANDEMIC MODULE 2.1- Visit to isolation ward PH 1.48 (Batch B)Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV (SEMINAR)	MI6.2, 6.3: Bordatella and Hemophilus(DOAP) Batch A + PANDEMIC MODULE 2.1- Visit to isolation ward. PH 1.48 (Batch B)Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV (SEMINAR)
21.7.22	Thurs	MI6.1: Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Orthomyxovirus (L)	Clinical Posting			PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Aminoglycosides) (L)	PA 27.10 Describe the etiology, pathophysiology, pathology features and complications of syphilis on the cardiovascular system	Patho (Batch B) FMT (Batch A)
22.7.22	Fri	OG (L) 13.1.5 and 13.1.7: Painrelief principles of induction and acceleration of labour, management of third stage of labor Og 14.2.1 and 14.2.2:Discuss the mechanism of normal labor, Define and describe obstructed labour, its clinical features, prevention and management	Clinical Posting			MI 6.1:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Aspergillus (SG)	PA 28.1Describe the normal histology of the kidney PA28.2 Define, classify and distinguish the clinical syndromes and describe the etiology, pathogenesis, pathology, morphology, clinical and laboratory and urinary findings, complications of renal failure	Patho (Batch A) FMT (Batch B)

23.7.22	3rd Sat	AETCOM 2.7: Case studies on patient autonomy and decision making (Pharmac) 2.6: Case studies on patient autonomy and decision making (Patho)	9:30 – 10:30pm	AETCOM2.7: Case studies on patient autonomy and decision making (Pharmac) 2.6: Case studies on patient autonomy and decision making (Patho)	MI6.2, 6.3: Bordatella and Hemophillus (DOAP) Batch B + PANDEMIC MODULE 2.1 PH 1.39 (Batch A) Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception ( Contraception )- SEMINAR	Sports	-	-
			10:30-11:30pm	PA27.7Pericarditis and other pericardial diseases.L				
			11:30-12:30pm	MI6.2, 6.3: Bordatella and Hemophillus (DOAP) Batch B + PANDEMIC MODULE 2.1PH 1.39 (batch A)Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception ( Contraception )- SEMINAR				



Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
25.7.22	Mon	MI 6.1: Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: M tuberculosis (Integrated)	Clinical Posting			PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (CDescribe and discuss the rational use of antimicrobials including antibiotic stewardship program (Fluoroquinolones )(L)	patho Skill Session Batch A (DOAP)	PH3.6 Batch B- Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs. SKILL LAB ( DOAP)
26.7.22	Tues	SU29.6 Describe the clinical features, investigations and principles of management of renal tumours				Days of Public Health Importance - I (SDL)	Patho Skill Session Batch B (DOAP)	PH3.6 Batch A- Demonstrate how to optimize interaction with pharmaceutical representative to get authentic information on drugs. SKILL LAB ( DOAP)
27.7.22	Wed	IM 16.15, 16.16, 16.18 (AITO-Integrated): Distinguish based on the clinical presentation Crohn’s disease from Ulcerative Colitis. Describe and enumerate the indications, pharmacology and side effects of pharmacotherapy including immunotherapy.Describe and enumerate the indications for surgery in inflammatory bowel disease				PA 28.5 Define and classify glomerular diseases. Enumerate and describe the etiology, pathogenesis, mechanisms of glomerular injury, pathology, distinguishing features and clinical manifestations of glomerulonephritis (L)	Micro practical revision Batch A	Micro practical revision Batch A PH1.43(SGT)-Batch B: Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Sulphonamides & Cotrimoxazole)
28.7.22	Thurs	MI6.1: Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Legionella (Sem)				PH1.43 Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Macrolides ) (L)	PA 28.3Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings, progression and complications of acute renal failure PA 28.4 Define and describe the etiology, precipitating factors, pathogenesis, pathology, laboratory urinary findings progression and complications of chronic renal failure (SGT)	FMT FM 2.21 - Mechanical asphyxia: Describe and discuss different types of hanging and strangulation including clinical findings, causes of death, post-mortem findings and medico-legal aspects of death due to hanging and strangulation including examination, preservation and dispatch of ligature material
29.7.22	Fri	OG 13.2 (L) : Define, describe the causes, pathophysiology,diagnosis investigations and management of preterm labour, PROM and postdated pregnancy and OG 14.1:Enumerate the diameters of Maternal Pelvis and types	Clinical Posting			MI 6.1:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: Adenovirus (Sem)	Pa 28.6 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of IgA nephropath(SGT)	FMT FM 2.21 - Mechanical asphyxia: Describe and discuss different types of hanging and strangulation including clinical findings, causes of death, post-mortem findings and medico-legal aspects of death due to hanging and strangulation including examination, preservation and dispatch of ligature material
30.7.22	4th Sat	FM 2.35 - Demonstrate professionalism while conducting autopsy in medicolegal situations, interpretation of findings and making inference/opinion, collection preservation and dispatch of biological or trace evidences FM3.1 - IDENTIFICATION	9:30 – 10:30pm	CM Revision	Micro practical revision Batch B Pharmac practical revision Batch A	Sports	-	-
			10:30- 11:30pm	PA 28.8 Enumerate and classify diseases affecting the tubular interstitium (L)				
			11:30- 12:30pm	Micro practical revision Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
1.8.22	Mon	MICRO Revision	Clinical Posting		Lunch	PH1.43(L): Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Tetracylines & Chloramphenicol)	Revision Patho (A),	PH 3.4 Batch B To recognise and report an adverse drug reaction- ADR -I (DOAP)
2.8.22	Tues	SU26.4 Describe the etiology, pathogenesis, clinical features of tumors of lung and the principles of management				Days of Public Health Importance- II (SDL)	Revision Patho (B)	PH 3.4 Batch A To recognise and report an adverse drug reaction- ADR -I (DOAP)
3.8.22	Wed	Med Revision				Patho Feedbacks and Reflections	Micro Feedbacks and Reflections	PH1.43(SGT)- Batch A: Describe and discuss the rational use of antimicrobials including
4.8.22	Thurs	MI6.1:Describe the etio-pathogenesis, laboratory diagnosis and prevention of Infections of upper and lower respiratory tract: other opportunistic fungi (SG)				PH1.44 Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses (L) .PH 1.45 Describe the drugs used in MDR and XDR Tuberculosis ( Anti-TB Drugs)	PA 28.7 Enumerate and describe the findings in glomerular manifestations of systemic disease (SGT)	Patho (Batch B) FMT (Batch A)
5.8.22	Fri	Ennumerate the diameters of Maternal Pelvis and types, Discuss the mechanism of normal labor, Define and describe obstructed				MICRO 2nd IA test	Patho Revision	FMT Revision
6.8.22	1st Sat	AETCOM 2.7: Case studies on patient autonomy and decision making (Pharmac) 2.6: Case studies on patient autonomy and decision making (Patho)	9:30 – 10:30pm	AETCOM 2.7: Case studies on patient autonomy and decision making (Pharmac) 2.6: Case studies on patient autonomy and decision making (Patho)	Micro practical Revision (Batch A)	AETCOM 2.7: Case studies on patient autonomy and decision making (Pharmac) 2.6: Case studies on patient autonomy and decision making (Patho)	Sports	-
			10:30-11:30pm	PA 28.9 Define and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, progression and complications of acute tubular necrosis(L)				
			11:30-12:30pm	Micro practical Revision (Batch A)				
				Pharm (Batch A)-practical Revision				

2nd Terminal Exam from 8th Aug to 22nd Aug 2022

Theory					
Date	Day	Time	Subject		
8.8.22	Mon	1-4pm	Patho		
9.8.22	Tues	1-4pm	Micro		
10.8.22	Wed	1-4pm	Pharmac		
11.8.22	Thurs	1-4pm	FMT		
12.8.22	Fri	1-4pm	CM		
14.8.22	Sat	9 to 12pm	Med		
15.8.22	Mon	1-4pm	Surg		
16.8.22	Tues	1-4pm	OBGY		
Practicals: 1pm onwards (Batches A to E)					
Date	Patho	Micro	Pharm	FMT	CM
17.8.22	A	B	C	D	E
18.8.22	E	A	B	C	D
19.8.22	D	E	A	B	C
20.8.22	C	D	E	A	B
22.8.22	B	C	D	E	A

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
23.8.22	Tues	Pharm- -PH1.47 - (L) Describe the mechanisms of action, types, doses, sideeffects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinalhelminthiasis (Antimalarial-1)	Clinical Posting			PA 28.13 Define classify and describe the etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features progression and complications of renal stone disease and obstructive uropathy (L)	PA28.10 & PA 28.14 Renal System DOAP	PH 3.4 Batch B To recognise and report an adverse drug reaction- ADR -II and ADR Reporting Systems & Forms (DOAP)
24.8.22	Wed	MI 7.1: Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: Herpes and CMV(L)	Clinical Posting			PA 28. 16 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of urothelial tumors (L)	PH 1.43 . Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Microbiology, Pediatrics, Medicine) Antibiotic stewardship program (INTEGRATED)	MI 2.5Describe the etio-pathogenesis and discuss the clinical evolution and the laboratory diagnosis of kalaazar, malaria, filariasis and other common parasites prevalent in India: Filaria (SDL)
25.8.22	Thurs	MI 7.2:Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures: T Pallidum (L)	Clinical Posting			Pharm- -PH1.47 - (L) Describe the mechanisms of action, types, doses, sideeffects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinalhelminthiasis (Antimalarial-2)	PA 28.11 Define classify and describe the etiology, pathogenesis pathology, laboratory, urinary findings, distinguishing features progression and complications of vascular disease of the kidney. (SGT)	PH1.45: Describe the dugs used in MDR and XDR Tuberculosis (Respiratory Medicine, Microbiology) INTEGRATED
26.8.22	Fri	M 17.3 : UTI (L)	Clinical Posting			MI 7.2: STDs (Integrated)	PA 28.12 Define classify and describe the genetics, inheritance, etiology, pathogenesis, pathology, laboratory, urinary findings, distinguishing features, progression and complications of cystic disease of the kidney ( SGT) MI 7.1:Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: Gonococcus (DOAP) Batch A	MI 7.1:Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: Gonococcus (DOAP) Batch A
		Pharm- -PH1.47 - (L) Describe the mechanisms of action, types, doses, sideeffects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinalhelminthiasis (Antiameobic& Other antiprotozoal Drugs)	9:30 – 10:30pm	Pharm- -PH1.47 - (L) Describe the mechanisms of action, types, doses, sideeffects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinalhelminthiasis (Antiameobic& Other antiprotozoal Drugs)	MI 7.1: Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: Gonococcus (DOAP) Batch A			

27.8.22	4 <sup>th</sup> Sat		10:30-11:30pm	MICRO- Revision		Sports	-	-
			11:30-12:30pm	PA 28.15 Describe the etiology, genetics, pathogenesis, pathology, presenting features and progression of thrombotic angiopathies (SGT) MI 7.1: Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: Gonococcus (DOAP) Batch A				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
29.8.22	Mon	PA 29.1 Classify testicular tumors and describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of testicular tumors (L)	Clinical Posting	Lunch	MI 8.1 Enumerate the microbial agents and their vectors causing Zoonotic diseases. Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: <i>Leptospira</i> and <i>Borrelia</i> (L)	PA 29.3 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, urologic findings & diagnostic tests of benign prostatic hyperplasia (DOAP) (MGT)	PH5.2 (Batch B)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider, PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance (DOAP)-RPh-1 & case study 1
30.8.22	Tues	PH1.55(L)-Describe and discuss the following National Health Programmes including Immunisation, Tuberculosis, Leprosy, Malaria, HIV, Filaria, Kala Azar, Diarrhoeal diseases, Anaemia& nutritional disorders, Blindness, Non-communicable diseases, cancer and Iodine deficiency -Antihelminthics	Clinical Posting		PA 29.2 Describe the pathogenesis, pathology, presenting and distinguishing features, diagnostic tests, progression and spread of carcinoma of the penis (L)	PA 29.3 Describe the pathogenesis, pathology, hormonal dependency presenting and distinguishing features, urologic findings & diagnostic tests of benign prostatic hyperplasia (DOAP) (MGT)	PH5.2 (Batch A)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider, PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance (DOAP)-RPh-1 & Case study 1
31.8.22	Wed	PUBLIC HOLIDAY - GANPATI			PUBLIC HOLIDAY - GANPATI	PUBLIC HOLIDAY - GANPATI	
1.9.22	Thurs	MI 8.1 Enumerate the microbial agents and their vectors causing Zoonotic diseases. Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: <i>E. granulosus</i> (L)	Clinical Posting		PH 1.48(L): Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV- Antifungal	PA 30.7 Describe the etiology, hormonal dependence, features and morphology of endometriosis (SGT)	PH1.43-Describe and discuss the rational use of antimicrobials including antibiotic stewardship program (Microbiology, Pediatrics, Medicine)- Typhoid INTEGRATED
2.9.22	Fri	MI 8.2Describe the etio-pathogenesis of opportunistic infections (OI) and discuss the factors contributing to the occurrence of OI, and the laboratory diagnosis: <i>Candida</i> (L)	Clinical Posting		MI 8.1 Enumerate the microbial agents and their vectors causing Zoonotic diseases. Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention Plague (SDL)	PA 30.8 Describe the etiology and morphologic features of adenomyosis (SGT) MI 7.2:Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures: spirochaetes (DOAP) Batch A	MI 7.2:Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures: spirochaetes (DOAP) Batch A

13.9. 22	1ST Sat	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	9:30 – 10:30pm	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch B	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)		Sports
			10:30-11:30pm	PH1.64 Describe overview of drug development; Phases of clinical trials and Good Clinical Practice (L) PANDEMIC MODULE				
			11:30-12:30pm	PH1.64 Describe overview of drug development; Phases of clinical trials and Good Clinical Practice (L) PANDEMIC MODULE				
				MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
5.9.22	Mon	PA 30.2 Describe the pathogenesis, etiology, pathology, diagnosis and progression and spread of carcinoma of the endometrium (L)	Clinical Posting			MI 5.1 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of meningitis: Cryptococcus and Mucor (L)	PA 30.3 FGT (DOAP) A Batch	PH5.2 (Batch B)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider, PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance (DOAP)-RPh-2 & Case study 2
6.9.22	Tues	PH 1.48(L): Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV-Antifungal-Antiviral	Clinical Posting			PA 30.1 Describe the epidemiology, pathogenesis, etiology, pathology, screening, diagnosis and progression of carcinoma of the cervix (L)	PA 30.3 FGT (DOAP) B Batch	PH5.2 (Batch B)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider, PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance (DOAP)-RPh-2 & Case study 2



7.9.22	Wed	MI 8.2Describe the etio-pathogenesis of opportunistic infections (OI) and discuss the factors contributing to the occurrence of OI, and the laboratory diagnosis: Histoplasma and Dimorphic fungi (L)	Clinical Posting		PA 30.4 Classify and describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of ovarian tumors (L)	PA 30.6 Describe the etiology and morphologic features of cervicitis (SGT)	PH5.2 (SGT)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider & PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance )RPh-1)
8.9.22	Thurs	MI 8.5Define Healthcare Associated Infections (HAI) and enumerate the types. Discuss the factors that contribute to the development of HAI and the methods for prevention: Pseudomonas and HAI and its control (L)	Clinical Posting		PH 1.48(L): Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV-STD	PA 30.9 Describe the etiology, hormonal dependence and morphology of endometrial hyperplasia (SGT)	PH5.2 (SGT)-Communicate with the patient regarding optimal use of a) drug therapy, b) devices and c) storage of medicines, PH5.3-Motivate patients with chronic diseases to adhere to the prescribed management by the health care provider & PH5.4-Explain to the patient the relationship between cost of treatment and patient compliance )RPh-2)
9.9.22	Fri	MI 8.3, 8.4: Describe the role of oncogenic viruses in the evolution of virus associated malignancy Describe the etiologic agents of emerging Infectious diseases. Discuss the clinical course and diagnosis : Oncogenic viruses emerging and reemerging infections (L)	Clinical Posting		MI 8.1Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: zoonosis and brucella (SG)	PA 32.1 Enumerate, classify and describe the etiology, pathogenesis, pathology and iodine dependency of thyroid swellings (SGT) MI 8.1 Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: Yersinia and Brucella (DOAP) Batch A	MI 8.1 Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: Yersinia and Brucella (DOAP) Batch A

10.9.22	2 <sup>nd</sup> Sat	PH 1.48(L): Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV & PH-1.62- Describe and discuss antiseptics and disinfectants (UTI)	9:30 – 10:30pm	PH1.44 Describe the first line antitubercular drugs, their mechanisms of action, side effects and doses (L) .PH 1.45 Describe the drugs used in MDR and XDR Tuberculosis ( Anti-Leprotic)	MI 8.1 Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: Yersinia and Brucella (DOAP) Batch B	Sports		-
			10:30- 11:30pm	MI 8.5: Define Healthcare Associated Infections (HAI) and enumerate the types. Discuss the factors that contribute to the development of HAI and the methods for prevention: HAI (Sem)				
			11:30- 12:30pm	PA 32.2Describe the etiology, cause, iodine dependency, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis (SGT)				
				MI 8.1 Describe the morphology, mode of transmission, pathogenesis and discuss the clinical course laboratory diagnosis and prevention: Yersinia and Brucella (DOAP) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
12.9.22	Mon	PA 30.5 Describe the etiology, pathogenesis, pathology, morphology, clinical course, spread and complications of gestational trophoblastic neoplasms (L)	Clinical Posting		MI8.2 Describe the etio-pathogenesis of opportunistic infections (OI) and discuss the factors contributing to the occurrence of OI, and the laboratory diagnosis: Candida (SDL)	PA 31.3 Breast & other endocrine organs (DOAP)	PH3.7 (Batch B)Prepare a list of essential medicines for a healthcare facility(DOAP)-To prepare and explain a list of P-drugs for a given case/condition
13.9.22	Tues	PH-1.49 (L)-Describe mechanism of action, classes, side effects, indications and contraindications of anticancer drugs-Anticancer drugs	Clinical Posting		PA 31.1 Classify and describe the types, etiology, pathogenesis, pathology and hormonal dependency of benign breast disease (L) PA 31.4 Enumerate and describe the etiology, hormonal dependency and pathogenesis of gynecomastia (L)	PA 31.3 Breast & other endocrine organs (DOAP)	PH3.7 (Batch A)Prepare a list of essential medicines for a healthcare facility(DOAP)-To prepare and explain a list of P-drugs for a given case/condition
14.9.22	Wed	MI 8.8:Describe the methods used and significance of assessing the microbial contamination of food, water and air: Microbiology of food, water and Air (L)+ MI 2.1: PANDEMIC MODULE 2.1- Case Discussion	Clinical Posting		PA 31.2Classify and describe the epidemiology, pathogenesis, classification, morphology, prognostic factors, hormonal dependency, staging and spread of carcinoma of the breast	PA 32.3 Describe the etiology, pathogenesis, manifestations, laboratory and imaging features and course of thyrotoxicosis/ hypothyroidism ( Integrated)	PH1.49 (SGT)-Describe mechanism of action, classes, side effects, indications and contraindications of anticancer drugs-Anticancer drugs
15.9.22	Thurs	MI 8.9: Discuss the appropriate method of collection of samples in the performance of laboratory tests in the detection of microbial agents causing infectious diseases: Collection of Sample (L)+ PANDEMIC MODULE 2.3- Interactive session	Clinical Posting		PH 1.50 (L)-Describe mechanisms of action, types, doses, side effects, indications and contraindications of immunomodulators and management of organ transplant rejection PH 1.54-Describe vaccines and their uses- Immunomodulators & Vaccines	PA 32.5 Describe the etiology, genetics, pathogenesis, manifestations, laboratory and morphologic features of hyperparathyroidism (SGT)	PH 1.47 (SGT)-Describe the mechanisms of action, types, doses, sideeffects, indications and contraindications of the drugs used in malaria, KALA-AZAR, amebiasis and intestinalhelminthiasis-SEMINAR - Malaria

16.9.22	Fri	MI 4.1 Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of anaerobic infections: clostridium perfringens (L)	Clinical Posting			PA 34.3 Describe the distinguishing features between a nevus and melanoma. Describe the etiology, pathogenesis, risk factors morphology clinical features and metastases of melanoma (L)	PA 36.1 Describe the etiology, genetics, pathogenesis, pathology, presentation, sequelae and complications of retinoblastoma ( Integrated)	PA33.3Classification, morphological features of lipomatous, fibrous, blood vessels tumours, Neural, muscle and fibro histiocytic tumours. (Small group discussion)PH 1.20 (SGT-Integrated) Describe the effects of acute and chronic ethanol intake (Psychiatry) -Ethyl and methyl alcoholol
17.9.22	3rdSat	AETCOM2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	AETCOM2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	11:30 to 12:30pm PA32.6 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications and metastases of pancreatic cancer(SGT) 11:30 to 12:30 MI 7.2: Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures: Spirochaetes (DOAP) Batch B	PA32.6 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications and metastases of pancreatic cancer(SGT) MI 7.2: Describe the etio-pathogenesis and discuss the laboratory diagnosis of sexually transmitted infections. Recommend preventive measures: Spirochaetes (DOAP) Batch B			

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
19.9.22	Mon	PA 32.4 Classify and describe the epidemiology, etiology, pathogenesis, pathology, clinical laboratory features, complications and progression of diabetes mellitus (L)	Clinical Posting		MI 8.5 Define Healthcare Associated Infections (HAI) and enumerate the types. Discuss the factors that contribute to the development of HAI and the methods for prevention: PUO (Integration)	Revision Practicals	Pharm (Batch B) practical PH3.1 Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient Multiple drug therapy (DOPAC)
20.9.22	Tues	PH 1.52 (L) Describe management of common poisoning, insecticides, common sting and bites & PH 1.53 Describe heavy metal poisoning and chelating agents-General Principles of Management of Poisoning	Clinical Posting		PA 32.7Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of adrenal insufficiency (Seminar)	Revision Practicals	Pharm (Batch A) practical PH3.1 Write a rational, correct and legible generic prescription for a given condition and communicate the same to the patient Multiple drug therapy (DOPAC)
21.9.22	Wed	MI8. 6Describe the basics of Infection control: Infection Control (Integration)+ PANDEMIC MODULE 2.1- Interactive session	Clinical Posting		Pa 32.8 Describe the etiology, pathogenesis, manifestations, laboratory, morphologic features, complications of Cushing's syndrome ( seminar)	PA 32.9 Describe the etiology, pathogenesis, manifestations, laboratory and morphologic features of adrenal neoplasms (SGT)	PH 1.44 (SGT)- Describe the first line antitubercular dugs, their mechanisms of action, side effects and doses.-SEMINAR -TB

22.9.22	Thurs	MI 8.9: Discuss the appropriate method of collection of samples in the performance of laboratory tests in the detection of microbial agents causing infectious diseases: Biomedical waste Disposal (SG)	Clinical Posting			PH 1.56 (L)Describe basic aspects of Geriatric and Pediatric pharmacology- Geriatric and Pediatric pharmacology	PA 33.3 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of soft tissue tumors (SGT)	PH1.48 (SGT)Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV-SEMINAR (UTI)
23.9.22	Fri	MI : 8.12: Discuss confidentiality pertaining to patient identity in laboratory results: Universal Safety Principles (L)	Clinical Posting			MI 8.16: Describe the National Health Programs in the prevention of common infectious disease (for information purpose only as taught in CM): Natinal health program in prevention of common infectious diseases (L)	PA 33.4 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of Paget's disease of the bone ( Integrated) MI 8.7: Demonstrate Infection control practices and use of Personal Protective Equipments (PPE): Pseudomonas and HAI , Hand hygiene certification (DOAP) Batch A	MI 8.7: Demonstrate Infection control practices and use of Personal Protective Equipments (PPE): Pseudomonas and HAI , Hand hygiene certification (DOAP) Batch A
24.9.22	4 <sup>th</sup> Sat	PH 1.57 (L) Describe drugs used in skin disorders-Drugs acting on skin and mucous membrane	9:30 – 10:30pm	PH 1.58 (L) Describe drugs used in Ocular disorders- Ocular Pharmacology	MI 8.7: Demonstrate Infection control practices and use of Personal Protective Equipments (PPE): Pseudomonas and HAI , Hand hygiene certification (DOAP) Batch B	Sports	-	-
			10:30-11:30pm	MI 8.4; Describe the etiologic agents of emerging Infectious diseases. Discuss the clinical course and diagnosis: Misc Bacteria (Sem)				
			11:30-12:30pm	PA 33.5 Classify and describe the etiology, immunology, pathogenesis, manifestations, radiologic and laboratory features, diagnostic criteria and complications of rheumatoid arthritis ( Integrated)				

				MI 8.7: Demonstrate Infection control practices and use of Personal Protective Equipments (PPE): Pseudomonas and HAI , Hand hygiene certification (DOAP) Batch B				

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
26.9.22	Mon	PA 33.1 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications of	Clinical Posting			MI 8.15: Choose and Interpret the results of the laboratory tests used in diagnosis of the infectious disease: serological reactions (SG)+ Pandemic Module 2.2- Small group activity	PA 20.1 Describe the features of plasma cell myeloma Identify, distinguish & skeletal system	Patho (Batch A) PH 3.8 (Batch B) Communicate effectively with a patient on the proper use of prescribed medication-Skill station: Steps for drug delivery (Topical and Inhalational)-DOAP
27.9.22	Tues	PH 1.59 (L) Describe and discuss the following: Essential medicines, Fixed dose combinations, Over the counter drugs, Herbal medicines PH 1.61-Describe and discuss dietary supplements and nutraceuticals-	Clinical Posting			PA 33.2 Classify and describe the etiology, pathogenesis, manifestations, radiologic and morphologic features and complications and metastases of bone tumors (L)	PA 20.1 Describe the features of plasma cell myeloma Identify, distinguish & skeletal system	PH 3.8 (Batch A) Communicate effectively with a patient on the proper use of prescribed medication-Skill station: Steps for drug delivery (Topical and Inhalational)-DOAP
28.9.22	Wed	MI 8.6:Describe the basics of Infection control: Needle stick injury (SDL)+ PANDEMIC MODULE 2.1- Debriefing and Feedback	Clinical Posting			PA 12.1 Enumerate and describe the pathogenesis of disorders caused by air pollution, tobacco and alcohol (L)	12.2 Describe the pathogenesis of disorders caused by protein calorie malnutrition and starvation (SGT)	PH1.48 (SGT)Describe the mechanisms of action, types, doses, side effects, indications and contraindications of the drugs used in UTI/ STD and viral diseases including HIV-SEMINAR (HIV)
29.9.22	Thurs	MI 8.6:Describe the basics of Infection control: Hand hygiene (SDL)	Clinical Posting			Pharm (L) Revision-G Pharma	PA 12.3 Describe the pathogenesis of obesity and its consequences(SGT)	PH 1.12 (SGT)Calculate the dosage of drugs using appropriate formulae for an individual patient, including children, elderly and patient with renal dysfunction. (Pediatrics and Medicine)-INTEGRATED-Dose modification in children, elderly & renal dysfn)
30.9.22	Fri	MI8.11: Demonstrate respect for patient samples sent to the laboratory for performance of laboratory tests in the detection of microbial agents	Clinical Posting			MI 8.15: Choose and Interpret the results of the laboratory tests used in diagnosis of the infectious disease: Molecular tests (SG)+ PANDEMIC MODULE2.2- Small group activity	REVISION PATHO (Batch B) MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch A	MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch A
1.10.22	1ST Sat	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	9:30 – 10:30pm	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)	MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss	AETCOM 2.8: What does it mean to be family member of a sick patient? (PSM) 2.4: Working in a health care team (Micro)		
			10:30- 11:30pm	PH1.64 Describe overview of drug development; Phases of clinical trials and Good Clinical Practice (L) PANDEMIC MODULE 2.4: Working in a health care team (Micro)				



1.10.22	1st Oct	2.4. Working in a health care team (Micro)	11:30-12:30pm	<div>PH1.64 Describe overview of drug development, Phases of clinical trials and Good Clinical Practice (L) PANDEMIC MODULE</div> <div>PH1.5 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch B</div>	the clinical course and the laboratory diagnosis: M leprae (DOAP) Batch B		Sports
---------	---------	--	---------------	---	---	--	--------

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
3.10.22	Mon	PA 34.1 Describe the risk factors pathogenesis, pathology and natural history of squamous cell carcinoma of the skin (L)	Clinical Posting	Lunch	MI 5.2 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of encephalitis: Rhabdo Virus (SDL)	PA 34.4 skin ( DAOP)	Patho (Batch A) Pharm (Batch B)-PH3.8 Communicate effectively with a patient on the proper use of prescribed medication Skill station: Steps for drug delivery
4.10.22	Tues	Pharmacology Revision-ANS & CVS	Clinical Posting		PA 34.2 Describe the risk factors pathogenesis, pathology and natural history of basal cell carcinoma of the skin(L)	PA 34.4 skin ( DAOP)	Patho (Batch B) Pharm (Batch A)-PH3.8 Communicate effectively with a patient on the proper use of prescribed medication Skill station: Steps for drug delivery (Topical and Inhalational)
5.10.22	Wed	PUBLIC HOLIDAY - DUSSEHRA			PUBLIC HOLIDAY - DUSSEHRA	PUBLIC HOLIDAY - DUSSEHRA	
6.10.22	Thurs	MI7.3:Describe the etio-pathogenesis, clinical features, the appropriate method for specimen collection, and discuss the laboratory diagnosis of Urinary tract infections: UTI (Sem)	Clinical Posting		Pharm- (L )PH1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists,	SDL (Patho)	PH1.21 (SGT-Integrated)Describe the symptoms and management of methanol and ethanol poisonings (Medicine)-Management of methanol and ethanol poisonings
7.10.22	Fri	MI 8.4:Describe the etiologic agents of emerging Infectious diseases. Discuss the clinical course and diagnosis: emerging and re-emerging infections (Integration)	Clinical Posting		MI 3.7: Describe the epidemiology, the etio-pathogenesis and discuss the viral markers in the evolution of Viral hepatitis. Discuss the modalities in the diagnosis and prevention of viral hepatitis: Liver fluke (SDL)	SDL (Patho) MI 4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Bacillus (DOAP) Batch A	MI 4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Bacillus (DOAP) Batch A

8.10.22	2 <sup>nd</sup> Sat	PH 1.23 Describe the process and mechanism of drug deaddiction (Psychiatry, Medicine) INTEGRATION	9:30 – 10:30pm	Pharm- L PH1.52 Describe management of common poisoning, insecticides, common sting	MI 4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Bacillus (DOAP) Batch A	Sports	-	-
			10:30- 11:30pm	MI 4.1 Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogene				
			11:30- 12:30pm	SDL (Patho)  MI 4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Bacillus (DOAP) Batch A				

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
10.10.22	Mon	PA 35.1 Describe the etiology, types and pathogenesis, differentiating factors, CSF findings in meningitis (L)	Clinical Posting	Lunch	MI 4.2: Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: Staphylococcus (L)	PA 35.3 Identify the etiology of meningitis based on given CSF parameters & CNS (DOAP)	Patho (Batch A) Pharm (Batch B)-practical PH3.8 Communicate effectively with a patient on the proper use of prescribed medication Skill station: Steps for drug delivery (Topical and Inhalational)
11.10.22	Tues	Pharmacology Revision- CNS & Endocrine	Clinical Posting		PA 35.2 Classify and describe the etiology, genetics, pathogenesis, pathology, presentation sequelae and complications of CNS tumors (L)	PA 35.3 Identify the etiology of meningitis based on given CSF parameters & CNS (DOAP)	Patho (Batch B) Pharm (Batch A)-practical PH3.8 Communicate effectively with a patient on the proper use of prescribed medication Skill station: Steps for drug delivery (Topical and Inhalational)
12.10.22	Wed	MI 4.2 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: MRSA Surveillance (SDL)	Clinical Posting		Patho revision	SDL (Patho)	PH 1.23 (SGT-Integrated) Describe the process and mechanism of drug deaddiction (Psychiatry, Medicine)-Principles of Deaddiction
13.10.22	Thurs	MI 4.1 Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of anaerobic infections: CI tetanii and CI botulism (L)	Clinical Posting		Pharmacology Revision- Chemotherapy-I	SDL (Patho)	PH 1.22 (SGT-INTEGRATED)Describe drugs of abuse (dependence, addiction, stimulants, depressants, psychedelics, drugs used for criminal offences)-CNS stimulants and Cognition Enhancers (Batch B) MICRO SKILL Session

14.10.22	Fri	MI 4.3Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: M . Leprae (L)	Clinical Posting			MicrMI 2.4 List the common microbial agents causing anemia. Describe the morphology, mode of infection and discuss the pathogenesis, clinical course diagnosis and prevention and treatment of the common microbial agents causing Anemia: Rickettsiae (SG)	SDL (Patho) MI 4.2Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: Staphylococcus (DOAP) Batch A	MI 4.2Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: Staphylococcus (DOAP) Batch A
15.10.22	3 <sup>rd</sup> Sat	AETCOM 2.4: Working in a health care team (Micro) 2.8: What does it mean to be family member of a sick patient? (PSM)	9:30 – 10:30pm	AETCOM 2.4 Working in a health care team (Micro) 2.8: What does it mean to be family member of a sick patient? (PSM)				
			10:30-11:30pm	MI8.13:Appropriate lab tests in diagnosis of infectious diseases (SEM)+ Pandemic Module 2.2- Discussion and Closure	MI 4.2Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: Staphylococcus (DOAP) Batch A		-	-
				RIVISION PATHO				

			11:30-12:30pm	MI 4.2Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of bone & joint infections: Staphylococcus (DOAP) Batch A				
--	--	--	---------------	---	--	--	--	--

Date	Day	8:30-9:30am	9:30 – 12:30pm	12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
17.10.22	Mon	Patho Revision	Clinical Posting	Lunch	MI 4.3Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: dermatophytes (L)	Patho Practical Revision	PathoPH3.4: (Batch B)To recognise and report an adverse drug reaction -Subjective & Obj effects of Drugs
18.10.22	Tues	Ph 1.20 (SDL) Acute and Chronic alcohol intake- Acute and Chronic alcohol intake	Clinical Posting		Patho revision	Patho Practical Revision	PH3.4: (Batch A)To recognise and report an adverse drug reaction -Subjective & Obj effects of Drugs
19.10.22	Wed	MI4.3 Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Actinomycetes (L)	Clinical Posting		Patho Revision	MI 4.3:Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Pox Virus (Sem)	Ph. 1.32 (SDL) Management of bronchial asthma
20.10.22	Thurs	MI4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: Mycetoma and s/c mycosis (Integrated)	Clinical Posting		Ph 1.20 (SDL) Acute and Chronic alcohol intake- Acute and Chronic alcohol intake	Seminar PH1.19 Describe the mechanism/s of action, types, doses, side effects, indications and contraindications of the drugs which act on CNS, (including anxiolytics, sedatives & hypnotics, anti-psychotic, anti- depressant drugs, anti-maniacs, opioid agonists and antagonists, drugs used for neurodegenerative disorders, anti-epileptics drugs) Parkinson’s disease	Ph. 1.32 (SDL) Management of bronchial asthma

21.10.22	Fri	MI 4.3: Describe the etio-pathogenesis of infections of skin and soft tissue and discuss the clinical course and the laboratory diagnosis: B anthracis (Integrated)	Clinical Posting			MI 5.2 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of encephalitis: Rabies Virus(L)	MI 4.1 Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of anaerobic infections: Clostridium and Non sporing (DOAP) Batch A	MI 4.1Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of anaerobic infections: Clostridium and Non sporing (DOAP) Batch A
22.10.22	4 <sup>th</sup> Sat	Ph 1.34 (SDL) inflammatory Bowel disease, Irritable bowel disorders, Billiary and pancreatic diseases- Inflammatory Bowel disease, Irritable bowel disorders, Billiary and pancreatic diseases	9:30 – 10:30pm	Ph 1.34 (SDL) inflammatory Bowel disease, Irritable bowel disorders, Billiary and pancreatic diseases- Inflammatory Bowel disease, Irritable bowel disorders, Billiary and pancreatic diseases		Sports	-	-
			10:30-11:30pm	MI5.2: Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of encephalitis: slow viral disease (seminar)				
			11:30-12:30pm	PA Revision				
				MI 4.1Enumerate the microbial agents causing anaerobic infections. Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of anaerobic infections: Clostridium and Non sporing (DOAP) Batch A				



DIWALI Vacation

Date	Day	8:30-9:30am	9:30 – 12:30pm		12:30-1:30pm	1:30 – 2:30pm	2:30-3:30pm	3:30-4:30pm
31.10.22	Mon	Patho Revision	Clinical Posting		Lunch	MI 5.1 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of meningitis: Meningococcus and Meningitis (Integrated)	Patho Practical Revision	Practical Revision (Batch B)
1.11.22	Tues	PH 1.22 (SDL) Drug abuse	Clinical Posting			Patho Revision	Patho Practical Revision	Practical Revision (Batch A)
2.11.22	Wed	MI5.1Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of meningitis: H influenzae (L)	Clinical Posting			Patho Revision	Patho Revision	Pharmac Feedback and Reflection
3.11.22	Thurs	3rd IA	Clinical Posting			PH 1.22 (SDL) Drug abuse	Seminar - Pharmac-PH1.39 Describe mechanism of action, types, doses, side effects, indications and contraindications the drugs used for contraception Contraception	Pharmac Feedback and Reflection
4.11.22	Fri	MI 5.1 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of meningitis: Toxoplasma (L)	Clinical Posting			MI 5.2 Describe the etiopathogenesis, clinical course and discuss the laboratory diagnosis of encephalitis: Polio virus (L)	MI 5.3: Identify the microbial agents causing meningitis: Microbial Agents causing Meningitis (DOAP) Batch A	MI 5.3: Identify the microbial agents causing meningitis: Microbial Agents causing Meningitis (DOAP) Batch A
			9:30 – 10:30pm	AETCOM2.4: Working in a health care team (Micro) 2.8: What does it mean to be family member of a sick patient? (PSM)				

5.11.22	1 <sup>st</sup> Sat	AETCOM 2.4: Working in a health care team (Micro) 2.8: What does it mean to be family member of a sick patient? (PSM)	10:30-11:30pm	MI 7.1:Describe the etio-pathogenesis and discuss the laboratory diagnosis of infections of genitourinary system: T vaginalis (Sem)	MI 5.3: Identify the microbial agents causing meningitis: Microbial Agents causing Meningitis (DOAP) Batch B	AETCOM 2.4: Working in a health care team (Micro) 2.8: What does it mean to be family member of a sick patient? (PSM)	Sports
			11:30-12:30pm	MI 5.3: Identify the microbial agents causing meningitis: Microbial Agents causing Meningitis (DOAP) Batch B			

PRELIM Exam 7.11.22 onwards

Theory			
Date	Day	Time	Subject
7.11.22	Mon	10am to 1pm	Patho 1
8.11.22	Tues	10am to 1pm	Patho2
9.11.22	Wed	10am to 1pm	Micro1
10.11.22	Thurs	10am to 1pm	Micro2
11.11.22	Fri	10am to 1pm	Pharm 1
12.11.22	Sat	10am to 1pm	Pharm 2

Practicals: 12:30 to 3:30 pm (Batches A to E)				
Date	Patho	Micro	Pharm	
14.11.22	A	B	C	
15.11.22	E	A	B	
16.11.22	D	E	A	
17.11.22	C	D	E	
18.11.22	B	C	D	